{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,16]],"date-time":"2026-11-16T22:14:30Z","timestamp":1794867270971,"version":"4.9.1"},"reference-count":262,"publisher":"Springer Science and Business Media LLC","issue":"10","license":[{"start":{"date-parts":[[2025,6,22]],"date-time":"2025-06-22T00:00:00Z","timestamp":1750550400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2025,6,22]],"date-time":"2025-06-22T00:00:00Z","timestamp":1750550400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Nat Rev Cardiol"],"published-print":{"date-parts":[[2025,10]]},"DOI":"10.1038\/s41569-025-01163-w","type":"journal-article","created":{"date-parts":[[2025,6,21]],"date-time":"2025-06-21T19:02:07Z","timestamp":1750532527000},"page":"728-750","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":59,"title":["Vascular (dys)function in the failing heart"],"prefix":"10.1038","volume":"22","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-1472-7975","authenticated-orcid":false,"given":"Luca","family":"Liberale","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2836-2241","authenticated-orcid":false,"given":"Dirk Jan","family":"Duncker","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Derek John","family":"Hausenloy","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8245-7287","authenticated-orcid":false,"given":"Simon","family":"Kraler","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hans Erik","family":"B\u00f8tker","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bruno Karl","family":"Podesser","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7078-4160","authenticated-orcid":false,"given":"Gerd","family":"Heusch","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3576-3772","authenticated-orcid":false,"given":"Petra","family":"Kleinbongard","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,6,22]]},"reference":[{"key":"1163_CR1","doi-asserted-by":"publisher","first-page":"409","DOI":"10.1016\/j.pcad.2014.12.002","volume":"57","author":"DJ Duncker","year":"2015","unstructured":"Duncker, D. J., Koller, A., Merkus, D. & Canty, J. M. Jr. Regulation of coronary blood flow in health and ischemic heart disease. Prog. Cardiovasc. Dis. 57, 409\u2013422 (2015).","journal-title":"Prog. Cardiovasc. Dis."},{"key":"1163_CR2","doi-asserted-by":"publisher","first-page":"321","DOI":"10.1002\/j.2040-4603.2017.tb00750.x","volume":"7","author":"AG Goodwill","year":"2017","unstructured":"Goodwill, A. G., Dick, G. M., Kiel, A. M. & Tune, J. D. Regulation of coronary blood flow. Compr. Physiol. 7, 321\u2013382 (2017).","journal-title":"Compr. Physiol."},{"key":"1163_CR3","doi-asserted-by":"publisher","first-page":"741","DOI":"10.1093\/cvr\/cvaa003","volume":"116","author":"T Padro","year":"2020","unstructured":"Padro, T. et al. ESC working group on coronary pathophysiology and microcirculation position paper on \u2018coronary microvascular dysfunction in cardiovascular disease\u2019. Cardiovasc. Res. 116, 741\u2013755 (2020).","journal-title":"Cardiovasc. Res."},{"key":"1163_CR4","doi-asserted-by":"publisher","first-page":"137","DOI":"10.1146\/annurev-physiol-031522-034807","volume":"85","author":"TA Longden","year":"2023","unstructured":"Longden, T. A., Zhao, G., Hariharan, A. & Lederer, W. J. Pericytes and the control of blood flow in brain and heart. Annu. Rev. Physiol. 85, 137\u2013164 (2023).","journal-title":"Annu. Rev. Physiol."},{"key":"1163_CR5","doi-asserted-by":"publisher","first-page":"106","DOI":"10.1038\/s41569-023-00913-y","volume":"21","author":"E Avolio","year":"2024","unstructured":"Avolio, E., Campagnolo, P., Katare, R. & Madeddu, P. The role of cardiac pericytes in health and disease: therapeutic targets for myocardial infarction. Nat. Rev. Cardiol. 21, 106\u2013118 (2024).","journal-title":"Nat. Rev. Cardiol."},{"key":"1163_CR6","doi-asserted-by":"publisher","first-page":"2336","DOI":"10.1093\/cvr\/cvae147","volume":"120","author":"T Dalkara","year":"2024","unstructured":"Dalkara, T., Ostergaard, L., Heusch, G. & Attwell, D. Pericytes in the brain and heart: functional roles and response to ischemia and reperfusion. Cardiovasc. Res. 120, 2336\u20132348 (2024).","journal-title":"Cardiovasc. Res."},{"key":"1163_CR7","doi-asserted-by":"publisher","first-page":"908","DOI":"10.1161\/01.RES.43.6.908","volume":"43","author":"KO Kelley","year":"1978","unstructured":"Kelley, K. O. & Feigl, E. O. Segmental alpha-receptor-mediated vasoconstriction in the canine coronary circulation. Circ. Res. 43, 908\u2013917 (1978).","journal-title":"Circ. Res."},{"key":"1163_CR8","doi-asserted-by":"publisher","first-page":"77","DOI":"10.1007\/3540528806_4","volume":"116","author":"E Bassenge","year":"1990","unstructured":"Bassenge, E. & Heusch, G. Endothelial and neuro-humoral control of coronary blood flow in health and disease. Rev. Physiol. Biochem. Pharmacol. 116, 77\u2013165 (1990).","journal-title":"Rev. Physiol. Biochem. Pharmacol."},{"key":"1163_CR9","first-page":"H779","volume":"251","author":"WM Chilian","year":"1986","unstructured":"Chilian, W. M., Eastham, C. L. & Marcus, M. L. Microvascular distribution of coronary vascular resistance in beating left ventricle. Am. J. Physiol. 251, H779\u2013H788 (1986).","journal-title":"Am. J. Physiol."},{"key":"1163_CR10","doi-asserted-by":"publisher","first-page":"409","DOI":"10.1007\/s00395-014-0409-x","volume":"109","author":"L Ostergaard","year":"2014","unstructured":"Ostergaard, L. et al. The role of capillary transit time heterogeneity in myocardial oxygenation and ischemic heart disease. Basic Res. Cardiol. 109, 409 (2014).","journal-title":"Basic Res. Cardiol."},{"key":"1163_CR11","doi-asserted-by":"publisher","DOI":"10.1038\/s41598-022-08357-z","volume":"12","author":"S Ebrahimi","year":"2022","unstructured":"Ebrahimi, S. & Bagchi, P. A computational study of red blood cell deformability effect on hemodynamic alteration in capillary vessel networks. Sci. Rep. 12, 4304 (2022).","journal-title":"Sci. Rep."},{"key":"1163_CR12","doi-asserted-by":"publisher","first-page":"806","DOI":"10.1093\/cvr\/cvaa023","volume":"116","author":"PG Camici","year":"2020","unstructured":"Camici, P. G., Tsch\u00f6pe, C., Di Carli, M. F., Rimoldi, O. & Van Linthout, S. Coronary microvascular dysfunction in hypertrophy and heart failure. Cardiovasc. Res. 116, 806\u2013816 (2020).","journal-title":"Cardiovasc. Res."},{"key":"1163_CR13","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1007\/s00395-022-00909-8","volume":"117","author":"G Heusch","year":"2022","unstructured":"Heusch, G. Coronary blood flow in heart failure: cause, consequence and bystander. Basic. Res. Cardiol. 117, 1 (2022).","journal-title":"Basic. Res. Cardiol."},{"key":"1163_CR14","doi-asserted-by":"publisher","DOI":"10.3389\/fcvm.2023.1153994","volume":"10","author":"T Toya","year":"2023","unstructured":"Toya, T., Nagatomo, Y., Ikegami, Y., Masaki, N. & Adachi, T. Coronary microvascular dysfunction in heart failure patients. Front. Cardiovasc. Med. 10, 1153994 (2023).","journal-title":"Front. Cardiovasc. Med."},{"key":"1163_CR15","doi-asserted-by":"publisher","first-page":"1519","DOI":"10.1093\/eurheartj\/ehi342","volume":"26","author":"A Repetto","year":"2005","unstructured":"Repetto, A. et al. Coronary atherosclerosis in end-stage idiopathic dilated cardiomyopathy: an innocent bystander? Eur. Heart J. 26, 1519\u20131527 (2005).","journal-title":"Eur. Heart J."},{"key":"1163_CR16","doi-asserted-by":"publisher","first-page":"1305","DOI":"10.1161\/CIRCHEARTFAILURE.121.008837","volume":"14","author":"JH Butt","year":"2021","unstructured":"Butt, J. H. et al. Efficacy and safety of dapagliflozin in heart failure with reduced ejection fraction according to N-terminal pro-B-type natriuretic peptide: insights from the DAPA-HF trial. Circ. Heart Fail. 14, 1305\u20131318 (2021).","journal-title":"Circ. Heart Fail."},{"key":"1163_CR17","doi-asserted-by":"publisher","first-page":"653","DOI":"10.1161\/01.CIR.0000025404.78001.D8","volume":"106","author":"JP Halcox","year":"2002","unstructured":"Halcox, J. P. et al. Prognostic value of coronary vascular endothelial dysfunction. Circulation 106, 653\u2013658 (2002).","journal-title":"Circulation"},{"key":"1163_CR18","doi-asserted-by":"publisher","first-page":"522","DOI":"10.1038\/s41569-021-00506-7","volume":"18","author":"G Heusch","year":"2021","unstructured":"Heusch, G. Myocardial stunning and hibernation revisited. Nat. Rev. Cardiol. 18, 522\u2013536 (2021).","journal-title":"Nat. Rev. Cardiol."},{"key":"1163_CR19","doi-asserted-by":"publisher","first-page":"265","DOI":"10.1038\/s41569-021-00632-2","volume":"19","author":"P Kleinbongard","year":"2022","unstructured":"Kleinbongard, P. & Heusch, G. A fresh look at coronary microembolization. Nat. Rev. Cardiol. 19, 265\u2013280 (2022).","journal-title":"Nat. Rev. Cardiol."},{"key":"1163_CR20","doi-asserted-by":"publisher","first-page":"263","DOI":"10.1016\/j.jacc.2013.02.092","volume":"62","author":"WJ Paulus","year":"2013","unstructured":"Paulus, W. J. & Tschope, C. A novel paradigm for heart failure with preserved ejection fraction: comorbidities drive myocardial dysfunction and remodeling through coronary microvascular endothelial inflammation. J. Am. Coll. Cardiol. 62, 263\u2013271 (2013).","journal-title":"J. Am. Coll. Cardiol."},{"key":"1163_CR21","doi-asserted-by":"publisher","DOI":"10.1161\/CIRCHEARTFAILURE.123.010805","volume":"17","author":"P Paolisso","year":"2024","unstructured":"Paolisso, P. et al. Coronary microvascular dysfunction in patients with heart failure: characterization of patterns in HFrEF versus HFpEF. Circ. Heart Fail. 17, e010805 (2024).","journal-title":"Circ. Heart Fail."},{"key":"1163_CR22","doi-asserted-by":"publisher","first-page":"722","DOI":"10.1161\/01.CIR.0000115525.92645.16","volume":"109","author":"GO von Mering","year":"2004","unstructured":"von Mering, G. O. et al. Abnormal coronary vasomotion as a prognostic indicator of cardiovascular events in women. Results from the National Heart, Lung, and Blood Institute-Sponsored Women\u2019s Ischemia Syndrome Evaluation (WISE). Circulation 109, 722\u2013725 (2004).","journal-title":"Circulation"},{"key":"1163_CR23","doi-asserted-by":"publisher","first-page":"1899","DOI":"10.1161\/01.CIR.101.16.1899","volume":"101","author":"V Sch\u00e4chinger","year":"2000","unstructured":"Sch\u00e4chinger, V., Britten, M. B. & Zeiher, A. M. Prognostic impact of coronary vasodilator dysfunction on adverse long-term outcome of coronary heart disease. Circulation 101, 1899\u20131906 (2000).","journal-title":"Circulation"},{"key":"1163_CR24","doi-asserted-by":"publisher","first-page":"948","DOI":"10.1161\/01.CIR.101.9.948","volume":"101","author":"JA Suwaidi","year":"2000","unstructured":"Suwaidi, J. A. et al. Long-term follow-up of patients with mild coronary artery disease and endothelial dysfunction. Circulation 101, 948\u2013954 (2000).","journal-title":"Circulation"},{"key":"1163_CR25","doi-asserted-by":"publisher","first-page":"795","DOI":"10.1161\/CIRCRESAHA.108.172528","volume":"102","author":"O Sorop","year":"2008","unstructured":"Sorop, O. et al. Functional and structural adaptations of coronary microvessels distal to a chronic coronary artery stenosis. Circ. Res. 102, 795\u2013803 (2008).","journal-title":"Circ. Res."},{"key":"1163_CR26","doi-asserted-by":"publisher","first-page":"2092","DOI":"10.1016\/j.jacc.2018.02.073","volume":"71","author":"G Siasos","year":"2018","unstructured":"Siasos, G. et al. Local low shear stress and endothelial dysfunction in patients with nonobstructive coronary atherosclerosis. J. Am. Coll. Cardiol. 71, 2092\u20132102 (2018).","journal-title":"J. Am. Coll. Cardiol."},{"key":"1163_CR27","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1152\/physrev.00023.2021","volume":"102","author":"WK Samson","year":"2022","unstructured":"Samson, W. K., Yosten, G. L. C. & Remme, C. A. A primer on obesity-related cardiomyopathy. Physiol. Rev. 102, 1\u20136 (2022).","journal-title":"Physiol. Rev."},{"key":"1163_CR28","doi-asserted-by":"publisher","first-page":"717","DOI":"10.1038\/s41569-024-01046-6","volume":"21","author":"MS Khan","year":"2024","unstructured":"Khan, M. S. et al. Global epidemiology of heart failure. Nat. Rev. Cardiol. 21, 717\u2013734 (2024).","journal-title":"Nat. Rev. Cardiol."},{"key":"1163_CR29","doi-asserted-by":"publisher","first-page":"269","DOI":"10.1038\/s41569-019-0315-x","volume":"17","author":"L Adamo","year":"2020","unstructured":"Adamo, L., Rocha-Resende, C., Prabhu, S. D. & Mann, D. L. Reappraising the role of inflammation in heart failure. Nat. Rev. Cardiol. 17, 269\u2013285 (2020).","journal-title":"Nat. Rev. Cardiol."},{"key":"1163_CR30","doi-asserted-by":"publisher","first-page":"837","DOI":"10.1016\/j.jacc.2021.12.017","volume":"79","author":"L Liberale","year":"2022","unstructured":"Liberale, L. et al. Inflammation, aging, and cardiovascular disease: JACC review topic of the week. J. Am. Coll. Cardiol. 79, 837\u2013847 (2022).","journal-title":"J. Am. Coll. Cardiol."},{"key":"1163_CR31","doi-asserted-by":"publisher","first-page":"2974","DOI":"10.1093\/eurheartj\/ehz961","volume":"41","author":"L Liberale","year":"2020","unstructured":"Liberale, L., Montecucco, F., Tardif, J. C., Libby, P. & Camici, G. G. Inflamm-ageing: the role of inflammation in age-dependent cardiovascular disease. Eur. Heart J. 41, 2974\u20132982 (2020).","journal-title":"Eur. Heart J."},{"key":"1163_CR32","doi-asserted-by":"publisher","first-page":"1263","DOI":"10.1152\/physrev.00029.2005","volume":"86","author":"N Westerhof","year":"2006","unstructured":"Westerhof, N., Boer, C., Lamberts, R. R. & Sipkema, P. Cross-talk between cardiac muscle and coronary vasculature. Physiol. Rev. 86, 1263\u20131308 (2006).","journal-title":"Physiol. Rev."},{"key":"1163_CR33","doi-asserted-by":"publisher","first-page":"56","DOI":"10.1038\/s41569-018-0087-8","volume":"16","author":"E Brakenhielm","year":"2019","unstructured":"Brakenhielm, E. & Alitalo, K. Cardiac lymphatics in health and disease. Nat. Rev. Cardiol. 16, 56\u201368 (2019).","journal-title":"Nat. Rev. Cardiol."},{"key":"1163_CR34","doi-asserted-by":"publisher","first-page":"117","DOI":"10.1161\/CIRCRESAHA.119.311148","volume":"125","author":"NG Frangogiannis","year":"2019","unstructured":"Frangogiannis, N. G. The extracellular matrix in ischemic and nonischemic heart failure. Circ. Res. 125, 117\u2013146 (2019).","journal-title":"Circ. Res."},{"key":"1163_CR35","doi-asserted-by":"publisher","first-page":"309","DOI":"10.1038\/s41569-022-00799-2","volume":"20","author":"M Pesce","year":"2023","unstructured":"Pesce, M. et al. Cardiac fibroblasts and mechanosensation in heart development, health and disease. Nat. Rev. Cardiol. 20, 309\u2013324 (2023).","journal-title":"Nat. Rev. Cardiol."},{"key":"1163_CR36","doi-asserted-by":"publisher","first-page":"386","DOI":"10.1038\/s41569-020-00489-x","volume":"18","author":"K Klaourakis","year":"2021","unstructured":"Klaourakis, K., Vieira, J. M. & Riley, P. R. The evolving cardiac lymphatic vasculature in development, repair and regeneration. Nat. Rev. Cardiol. 18, 386\u2013379 (2021).","journal-title":"Nat. Rev. Cardiol."},{"key":"1163_CR37","doi-asserted-by":"publisher","first-page":"238","DOI":"10.1038\/nrcardio.2016.203","volume":"14","author":"DA Brown","year":"2017","unstructured":"Brown, D. A. et al. Expert consensus document: mitochondrial function as a therapeutic target in heart failure. Nat. Rev. Cardiol. 14, 238\u2013250 (2017).","journal-title":"Nat. Rev. Cardiol."},{"key":"1163_CR38","doi-asserted-by":"publisher","first-page":"H29","DOI":"10.1152\/ajpheart.00531.2024","volume":"328","author":"CA Gutierrez-Huerta","year":"2025","unstructured":"Gutierrez-Huerta, C. A., Quiroz-Delfi, G., Faleel, F. D. M. & Beyer, A. M. Impaired endothelial function contributes to cardiac dysfunction: role of mitochondrial dynamics. Am. J. Physiol. Heart Circ. Physiol. 328, H29\u2013H36 (2025).","journal-title":"Am. J. Physiol. Heart Circ. Physiol."},{"key":"1163_CR39","doi-asserted-by":"publisher","first-page":"817","DOI":"10.1042\/CS20220797","volume":"138","author":"J Toton-Zuranska","year":"2024","unstructured":"Toton-Zuranska, J., Mikolajczyk, T. P., Saju, B. & Guzik, T. J. Vascular remodelling in cardiovascular diseases: hypertension, oxidation, and inflammation. Clin. Sci. 138, 817\u2013850 (2024).","journal-title":"Clin. Sci."},{"key":"1163_CR40","doi-asserted-by":"publisher","first-page":"1933","DOI":"10.1016\/S0140-6736(14)60107-0","volume":"383","author":"G Heusch","year":"2014","unstructured":"Heusch, G. et al. Cardiovascular remodeling in coronary artery disease and heart failure. Lancet 383, 1933\u20131943 (2014).","journal-title":"Lancet"},{"key":"1163_CR41","doi-asserted-by":"publisher","first-page":"1009","DOI":"10.1152\/physrev.00045.2006","volume":"88","author":"DJ Duncker","year":"2008","unstructured":"Duncker, D. J. & Bache, R. J. Regulation of coronary blood flow during exercise. Physiol. Rev. 88, 1009\u20131086 (2008).","journal-title":"Physiol. Rev."},{"key":"1163_CR42","doi-asserted-by":"publisher","first-page":"689","DOI":"10.1161\/01.CIR.101.6.689","volume":"101","author":"G Heusch","year":"2000","unstructured":"Heusch, G. et al. \u03b1-Adrenergic coronary vasoconstriction and myocardial ischemia in humans. Circulation 101, 689\u2013694 (2000).","journal-title":"Circulation"},{"key":"1163_CR43","doi-asserted-by":"publisher","first-page":"1046","DOI":"10.1056\/NEJM198610233151702","volume":"315","author":"PL Ludmer","year":"1986","unstructured":"Ludmer, P. L. et al. Paradoxical vasoconstriction induced by acetylcholine in atherosclerotic coronary arteries. N. Engl. J. Med. 315, 1046\u20131051 (1986).","journal-title":"N. Engl. J. Med."},{"key":"1163_CR44","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1152\/physiolgenomics.00062.2017","volume":"50","author":"HC Saternos","year":"2018","unstructured":"Saternos, H. C. et al. Distribution and function of the muscarinic receptor subtypes in the cardiovascular system. Physiol. Genomics 50, 1\u20139 (2018).","journal-title":"Physiol. Genomics"},{"key":"1163_CR45","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/j.jjcc.2024.01.005","volume":"84","author":"T Sato","year":"2024","unstructured":"Sato, T., Hanna, P. & Mori, S. Innervation of the coronary arteries and its role in controlling microvascular resistance. J. Cardiol. 84, 1\u201313 (2024).","journal-title":"J. Cardiol."},{"key":"1163_CR46","doi-asserted-by":"publisher","first-page":"1352","DOI":"10.1016\/j.jacc.2021.07.042","volume":"78","author":"MG Del Buono","year":"2021","unstructured":"Del Buono, M. G. et al. Coronary microvascular dysfunction across the spectrum of cardiovascular diseases: JACC state-of-the-art review. J. Am. Coll. Cardiol. 78, 1352\u20131371 (2021).","journal-title":"J. Am. Coll. Cardiol."},{"key":"1163_CR47","doi-asserted-by":"publisher","first-page":"1857","DOI":"10.1093\/cvr\/cvab222","volume":"118","author":"G Grassi","year":"2022","unstructured":"Grassi, G., Mancia, G. & Esler, M. Central and peripheral sympathetic activation in heart failure. Cardiovasc. Res. 118, 1857\u20131871 (2022).","journal-title":"Cardiovasc. Res."},{"key":"1163_CR48","doi-asserted-by":"publisher","first-page":"358","DOI":"10.1124\/pharmrev.123.000831","volume":"76","author":"D Maaliki","year":"2024","unstructured":"Maaliki, D., Jaffa, A. A., Nasser, S., Sahebkar, A. & Eid, A. H. Adrenoceptor desensitization: current understanding of mechanisms. Pharmacol. Rev. 76, 358\u2013387 (2024).","journal-title":"Pharmacol. Rev."},{"key":"1163_CR49","doi-asserted-by":"publisher","first-page":"1573","DOI":"10.1161\/01.CIR.90.3.1573","volume":"90","author":"P Golino","year":"1994","unstructured":"Golino, P. & Maseri, A. Serotonin receptors in human coronary arteries. Circulation 90, 1573\u20131575 (1994).","journal-title":"Circulation"},{"key":"1163_CR50","doi-asserted-by":"publisher","first-page":"26","DOI":"10.1016\/j.yjmcc.2024.05.004","volume":"192","author":"PE McCallinhart","year":"2024","unstructured":"McCallinhart, P. E., Chade, A. R., Bender, S. B. & Trask, A. J. Expanding landscape of coronary microvascular disease in co-morbid conditions: metabolic disease and beyond. J. Mol. Cell Cardiol. 192, 26\u201335 (2024).","journal-title":"J. Mol. Cell Cardiol."},{"key":"1163_CR51","doi-asserted-by":"publisher","DOI":"10.1016\/j.vph.2024.107393","volume":"156","author":"D Manning","year":"2024","unstructured":"Manning, D., Rivera, E. J. & Santana, L. F. The life cycle of a capillary: mechanisms of angiogenesis and rarefaction in microvascular physiology and pathologies. Vasc. Pharmacol. 156, 107393 (2024).","journal-title":"Vasc. Pharmacol."},{"key":"1163_CR52","doi-asserted-by":"publisher","first-page":"27022","DOI":"10.1073\/pnas.1922755117","volume":"117","author":"AL Gonzales","year":"2020","unstructured":"Gonzales, A. L. et al. Contractile pericytes determine the direction of blood flow at capillary junctions. Proc. Natl Acad. Sci. USA 117, 27022\u201327033 (2020).","journal-title":"Proc. Natl Acad. Sci. USA"},{"key":"1163_CR53","doi-asserted-by":"publisher","first-page":"207","DOI":"10.1002\/2211-5463.13021","volume":"11","author":"LL Lee","year":"2021","unstructured":"Lee, L. L., Khakoo, A. Y. & Chintalgattu, V. Cardiac pericytes function as key vasoactive cells to regulate homeostasis and disease. FEBS Open Bio 11, 207\u2013225 (2021).","journal-title":"FEBS Open Bio"},{"key":"1163_CR54","doi-asserted-by":"publisher","DOI":"10.1161\/JAHA.123.032213","volume":"13","author":"DT Mathew","year":"2024","unstructured":"Mathew, D. T. et al. Associations of circulating vascular cell adhesion molecule-1 and intercellular adhesion molecule-1 with long-term cardiac function. J. Am. Heart Assoc. 13, e032213 (2024).","journal-title":"J. Am. Heart Assoc."},{"key":"1163_CR55","doi-asserted-by":"publisher","first-page":"1596","DOI":"10.1093\/cvr\/cvz156","volume":"115","author":"J Pernow","year":"2019","unstructured":"Pernow, J., Mahdi, A., Yang, J. & Zhou, Z. Red blood cell dysfunction: a new player in cardiovascular disease. Cardiovasc. Res. 115, 1596\u20131605 (2019).","journal-title":"Cardiovasc. Res."},{"key":"1163_CR56","doi-asserted-by":"publisher","DOI":"10.1002\/ehf2.15090","author":"G D\u2019Italia","year":"2024","unstructured":"D\u2019Italia, G., Schroen, B. & Cosemans, J. Commonalities of platelet dysfunction in heart failure with preserved ejection fraction and underlying comorbidities. ESC Heart Fail. https:\/\/doi.org\/10.1002\/ehf2.15090 (2024).","journal-title":"ESC Heart Fail."},{"key":"1163_CR57","doi-asserted-by":"publisher","first-page":"811","DOI":"10.1038\/ncpcardio1364","volume":"5","author":"AJ Ijsselmuiden","year":"2008","unstructured":"Ijsselmuiden, A. J. et al. Circulating white blood cells and platelets amplify oxidative stress in heart failure. Nat. Clin. Pract. Cardiovasc. Med. 5, 811\u2013820 (2008).","journal-title":"Nat. Clin. Pract. Cardiovasc. Med."},{"key":"1163_CR58","doi-asserted-by":"publisher","first-page":"1534","DOI":"10.1002\/ehf2.12700","volume":"7","author":"C Hage","year":"2020","unstructured":"Hage, C. et al. Myeloperoxidase and related biomarkers are suggestive footprints of endothelial microvascular inflammation in HFpEF patients. Esc. Heart Fail. 7, 1534\u20131546 (2020).","journal-title":"Esc. Heart Fail."},{"key":"1163_CR59","doi-asserted-by":"publisher","first-page":"2610","DOI":"10.1093\/cvr\/cvab306","volume":"118","author":"T Mohaissen","year":"2022","unstructured":"Mohaissen, T. et al. Temporal relationship between systemic endothelial dysfunction and alterations in erythrocyte function in a murine model of chronic heart failure. Cardiovasc. Res. 118, 2610\u20132624 (2022).","journal-title":"Cardiovasc. Res."},{"key":"1163_CR60","doi-asserted-by":"publisher","first-page":"1945","DOI":"10.1016\/j.jacc.2004.07.056","volume":"44","author":"M Madjid","year":"2004","unstructured":"Madjid, M., Awan, I., Willerson, J. T. & Casscells, S. W. Leukocyte count and coronary heart disease: implications for risk assessment. J. Am. Coll. Cardiol. 44, 1945\u20131956 (2004).","journal-title":"J. Am. Coll. Cardiol."},{"key":"1163_CR61","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-022-35323-0","volume":"13","author":"J Joseph","year":"2022","unstructured":"Joseph, J. et al. Genetic architecture of heart failure with preserved versus reduced ejection fraction. Nat. Commun. 13, 7753 (2022).","journal-title":"Nat. Commun."},{"key":"1163_CR62","doi-asserted-by":"publisher","first-page":"524","DOI":"10.1038\/s41586-021-03392-8","volume":"592","author":"P Libby","year":"2021","unstructured":"Libby, P. The changing landscape of atherosclerosis. Nature 592, 524\u2013533 (2021).","journal-title":"Nature"},{"key":"1163_CR63","doi-asserted-by":"publisher","first-page":"864","DOI":"10.1161\/CIRCRESAHA.121.318061","volume":"128","author":"P Boutouyrie","year":"2021","unstructured":"Boutouyrie, P., Chowienczyk, P., Humphrey, J. D. & Mitchell, G. F. Arterial stiffness and cardiovascular risk in hypertension. Circ. Res. 128, 864\u2013886 (2021).","journal-title":"Circ. Res."},{"key":"1163_CR64","doi-asserted-by":"publisher","first-page":"248","DOI":"10.1016\/0735-1097(92)90167-L","volume":"20","author":"M Packer","year":"1992","unstructured":"Packer, M. The neurohormonal hypothesis: a theory to explain the mechanism of disease progression in heart failure. J. Am. Coll. Cardiol. 20, 248\u2013254 (1992).","journal-title":"J. Am. Coll. Cardiol."},{"key":"1163_CR65","doi-asserted-by":"publisher","first-page":"117","DOI":"10.1002\/ejhf.3072","volume":"26","author":"SV Nesterov","year":"2024","unstructured":"Nesterov, S. V. et al. Short-term effects of sacubitril\/valsartan therapy on myocardial oxygen consumption and energetic efficiency of cardiac work in heart failure with reduced ejection fraction: a randomized controlled study. Eur. J. Heart Fail. 26, 117\u2013126 (2024).","journal-title":"Eur. J. Heart Fail."},{"key":"1163_CR66","doi-asserted-by":"publisher","DOI":"10.1161\/CIRCHEARTFAILURE.117.004129","volume":"10","author":"K Weiss","year":"2017","unstructured":"Weiss, K. et al. Fatigability, exercise intolerance, and abnormal skeletal muscle energetics in heart failure. Circ. Heart Fail. 10, e004129 (2017).","journal-title":"Circ. Heart Fail."},{"key":"1163_CR67","doi-asserted-by":"publisher","DOI":"10.1161\/CIRCHEARTFAILURE.120.007308","volume":"14","author":"M Fudim","year":"2021","unstructured":"Fudim, M., Sobotka, P. A. & Dunlap, M. E. Extracardiac abnormalities of preload reserve: mechanisms underlying exercise limitation in heart failure with preserved ejection fraction, autonomic dysfunction, and liver disease. Circ. Heart Fail. 14, e007308 (2021).","journal-title":"Circ. Heart Fail."},{"key":"1163_CR68","doi-asserted-by":"publisher","first-page":"1011","DOI":"10.1002\/ejhf.1156","volume":"20","author":"R Zymlinski","year":"2018","unstructured":"Zymlinski, R. et al. Increased blood lactate is prevalent and identifies poor prognosis in patients with acute heart failure without overt peripheral hypoperfusion. Eur. J. Heart Fail. 20, 1011\u20131018 (2018).","journal-title":"Eur. J. Heart Fail."},{"key":"1163_CR69","doi-asserted-by":"publisher","first-page":"148","DOI":"10.1016\/j.jacc.2019.10.058","volume":"75","author":"CL Fanola","year":"2020","unstructured":"Fanola, C. L. et al. Incident heart failure and long-term risk for venous thromboembolism. J. Am. Coll. Cardiol. 75, 148\u2013158 (2020).","journal-title":"J. Am. Coll. Cardiol."},{"key":"1163_CR70","doi-asserted-by":"publisher","DOI":"10.1161\/CIRCHEARTFAILURE.121.008934","volume":"15","author":"NK Kapur","year":"2022","unstructured":"Kapur, N. K. et al. Intermittent occlusion of the superior vena cava to improve hemodynamics in patients with acutely decompensated heart failure: the venus-hf early feasibility study. Circ. Heart Fail. 15, e008934 (2022).","journal-title":"Circ. Heart Fail."},{"key":"1163_CR71","doi-asserted-by":"publisher","DOI":"10.1001\/jamacardio.2024.2612","author":"M Fudim","year":"2024","unstructured":"Fudim, M. et al. Endovascular ablation of the greater splanchnic nerve in heart failure with preserved ejection fraction: the rebalance-HF randomized clinical trial. JAMA Cardiol. https:\/\/doi.org\/10.1001\/jamacardio.2024.2612 (2024).","journal-title":"JAMA Cardiol."},{"key":"1163_CR72","doi-asserted-by":"publisher","first-page":"2825","DOI":"10.1093\/eurheartj\/ehy331","volume":"39","author":"TM Gorter","year":"2018","unstructured":"Gorter, T. M., Obokata, M., Reddy, Y. N. V., Melenovsky, V. & Borlaug, B. A. Exercise unmasks distinct pathophysiologic features in heart failure with preserved ejection fraction and pulmonary vascular disease. Eur. Heart J. 39, 2825\u20132835 (2018).","journal-title":"Eur. Heart J."},{"key":"1163_CR73","doi-asserted-by":"publisher","first-page":"1042","DOI":"10.1161\/HYPERTENSIONAHA.115.05846","volume":"66","author":"Q Zhao","year":"2015","unstructured":"Zhao, Q. et al. Effects of intrinsic and extrinsic cardiac nerves on atrial arrhythmia in experimental pulmonary artery hypertension. Hypertension 66, 1042\u20131049 (2015).","journal-title":"Hypertension"},{"key":"1163_CR74","doi-asserted-by":"publisher","first-page":"eaao0303","DOI":"10.1126\/scitranslmed.aao0303","volume":"10","author":"E Legchenko","year":"2018","unstructured":"Legchenko, E. et al. PPAR\u03b3 agonist pioglitazone reverses pulmonary hypertension and prevents right heart failure via fatty acid oxidation. Sci. Transl. Med. 10, eaao0303 (2018).","journal-title":"Sci. Transl. Med."},{"key":"1163_CR75","doi-asserted-by":"publisher","first-page":"920","DOI":"10.1161\/CIRCULATIONAHA.109.933762","volume":"122","author":"E Soon","year":"2010","unstructured":"Soon, E. et al. Elevated levels of inflammatory cytokines predict survival in idiopathic and familial pulmonary arterial hypertension. Circulation 122, 920\u2013927 (2010).","journal-title":"Circulation"},{"key":"1163_CR76","doi-asserted-by":"publisher","first-page":"2817","DOI":"10.1016\/j.jacc.2020.10.022","volume":"76","author":"G Rossitto","year":"2020","unstructured":"Rossitto, G. et al. Reduced lymphatic reserve in heart failure with preserved ejection fraction. J. Am. Coll. Cardiol. 76, 2817\u20132829 (2020).","journal-title":"J. Am. Coll. Cardiol."},{"key":"1163_CR77","doi-asserted-by":"publisher","first-page":"zqae033","DOI":"10.1093\/function\/zqae033","volume":"5","author":"HJ Kim","year":"2024","unstructured":"Kim, H. J., Norton, C. E., Zawieja, S. D., Castorena-Gonzalez, J. A. & Davis, M. J. Acute metabolic stress induces lymphatic dysfunction through KATP channel activation. Function 5, zqae033 (2024).","journal-title":"Function"},{"key":"1163_CR78","doi-asserted-by":"publisher","first-page":"3402","DOI":"10.1172\/JCI97192","volume":"128","author":"JM Vieira","year":"2018","unstructured":"Vieira, J. M. et al. The cardiac lymphatic system stimulates resolution of inflammation following myocardial infarction. J. Clin. Invest. 128, 3402\u20133412 (2018).","journal-title":"J. Clin. Invest."},{"key":"1163_CR79","doi-asserted-by":"publisher","first-page":"1684","DOI":"10.1161\/CIRCULATIONAHA.123.065935","volume":"150","author":"Z Duan","year":"2024","unstructured":"Duan, Z. et al. Bone morphogenetic protein 9 protects against myocardial infarction by improving lymphatic drainage function and triggering DECR1-mediated mitochondrial bioenergetics. Circulation 150, 1684\u20131701 (2024).","journal-title":"Circulation"},{"key":"1163_CR80","doi-asserted-by":"publisher","first-page":"113","DOI":"10.1007\/s11897-023-00595-0","volume":"20","author":"HM Salah","year":"2023","unstructured":"Salah, H. M., Biegus, J. & Fudim, M. Role of the renal lymphatic system in heart failure. Curr. Heart Fail. Rep. 20, 113\u2013120 (2023).","journal-title":"Curr. Heart Fail. Rep."},{"key":"1163_CR81","doi-asserted-by":"publisher","first-page":"1484","DOI":"10.1161\/CIRCULATIONAHA.115.020143","volume":"133","author":"O Henri","year":"2016","unstructured":"Henri, O. et al. Selective stimulation of cardiac lymphangiogenesis reduces myocardial edema and fibrosis leading to improved cardiac function following myocardial infarction. Circulation 133, 1484\u20131497 (2016).","journal-title":"Circulation"},{"key":"1163_CR82","doi-asserted-by":"publisher","first-page":"62","DOI":"10.1038\/nature14483","volume":"522","author":"L Klotz","year":"2015","unstructured":"Klotz, L. et al. Cardiac lymphatics are heterogeneous in origin and respond to injury. Nature 522, 62\u201367 (2015).","journal-title":"Nature"},{"key":"1163_CR83","doi-asserted-by":"publisher","first-page":"872","DOI":"10.1016\/j.jacbts.2021.09.008","volume":"6","author":"WT Abraham","year":"2021","unstructured":"Abraham, W. T. et al. Direct interstitial decongestion in an animal model of acute-on-chronic ischemic heart failure. JACC Basic Transl. Sci. 6, 872\u2013881 (2021).","journal-title":"JACC Basic Transl. Sci."},{"key":"1163_CR84","first-page":"61","volume":"56","author":"M Wald","year":"2023","unstructured":"Wald, M., Svobodova, J. & Krizova, H. Modified lymphoscintigraphy in primary lymphatic insufficiency of the lower limb. Lymphology 56, 61\u201371 (2023).","journal-title":"Lymphology"},{"key":"1163_CR85","doi-asserted-by":"publisher","DOI":"10.1038\/s41598-023-40826-x","volume":"13","author":"H Cheon","year":"2023","unstructured":"Cheon, H., Kim, S. A., Kim, B. & Jeon, J. Y. Investigation of optimizing indocyanine green solution for in vivo lymphatic research using near-infrared fluorescence indocyanine green lymphangiography. Sci. Rep. 13, 14966 (2023).","journal-title":"Sci. Rep."},{"key":"1163_CR86","doi-asserted-by":"publisher","first-page":"250","DOI":"10.1055\/s-0040-1713442","volume":"37","author":"CC Pieper","year":"2020","unstructured":"Pieper, C. C. Nodal and pedal MR lymphangiography of the central lymphatic system: techniques and applications. Semin. Interv. Radiol. 37, 250\u2013262 (2020).","journal-title":"Semin. Interv. Radiol."},{"key":"1163_CR87","doi-asserted-by":"publisher","first-page":"237","DOI":"10.1055\/s-0040-1713441","volume":"37","author":"FR Schwartz","year":"2020","unstructured":"Schwartz, F. R. et al. Lymphatic imaging: current noninvasive and invasive techniques. Semin. Interv. Radiol. 37, 237\u2013249 (2020).","journal-title":"Semin. Interv. Radiol."},{"key":"1163_CR88","doi-asserted-by":"crossref","first-page":"1258","DOI":"10.1161\/01.CIR.93.8.1556","volume":"93","author":"G Heusch","year":"1996","unstructured":"Heusch, G., Schulz, R. & Baumgart, D. Dobutamine induces a biphasic response in dysfunctional left ventricular regions. Circulation 93, 1258\u20131260 (1996).","journal-title":"Circulation"},{"key":"1163_CR89","doi-asserted-by":"publisher","DOI":"10.1161\/HCI.0000000000000053","volume":"13","author":"MJ Garcia","year":"2020","unstructured":"Garcia, M. J. et al. State of the art: imaging for myocardial viability: a scientific statement from the American Heart Association. Circ. Cardiovasc. Imaging 13, e000053 (2020).","journal-title":"Circ. Cardiovasc. Imaging"},{"key":"1163_CR90","doi-asserted-by":"publisher","first-page":"668","DOI":"10.1067\/mhj.2002.120968","volume":"143","author":"H Okayama","year":"2002","unstructured":"Okayama, H. et al. Usefulness of an echo-contrast agent for assessment of coronary flow velocity and coronary flow velocity reserve in the left anterior descending coronary artery with transthoracic Doppler scan echocardiography. Am. Heart J. 143, 668\u2013675 (2002).","journal-title":"Am. Heart J."},{"key":"1163_CR91","doi-asserted-by":"publisher","first-page":"7845","DOI":"10.3934\/mbe.2023339","volume":"20","author":"J Zhang","year":"2023","unstructured":"Zhang, J. et al. Early diagnosis of coronary microvascular dysfunction by myocardial contrast stress echocardiography. Math. Biosci. Eng. 20, 7845\u20137858 (2023).","journal-title":"Math. Biosci. Eng."},{"key":"1163_CR92","doi-asserted-by":"publisher","first-page":"673","DOI":"10.1016\/S0735-1097(87)80212-7","volume":"10","author":"BD Guth","year":"1987","unstructured":"Guth, B. D., Martin, J. F., Heusch, G. & Ross, J. Jr. Regional myocardial blood flow, function and metabolism using phosphorus-31 nuclear magnetic resonance spectroscopy during ischemia and reperfusion in dogs. J. Am. Coll. Cardiol. 10, 673\u2013681 (1987).","journal-title":"J. Am. Coll. Cardiol."},{"key":"1163_CR93","doi-asserted-by":"publisher","first-page":"1787","DOI":"10.2174\/138161208784746743","volume":"14","author":"M ten Hove","year":"2008","unstructured":"ten Hove, M. & Neubauer, S. The application of NMR spectroscopy for the study of heart failure. Curr. Pharm. Des. 14, 1787\u20131797 (2008).","journal-title":"Curr. Pharm. Des."},{"key":"1163_CR94","doi-asserted-by":"publisher","first-page":"1228","DOI":"10.1161\/CIRCRESAHA.114.303551","volume":"114","author":"CA Lygate","year":"2014","unstructured":"Lygate, C. A. & Neubauer, S. Metabolic flux as a predictor of heart failure prognosis. Circ. Res. 114, 1228\u20131230 (2014).","journal-title":"Circ. Res."},{"key":"1163_CR95","doi-asserted-by":"publisher","first-page":"1302","DOI":"10.1093\/ehjci\/jead124","volume":"24","author":"J Pan","year":"2023","unstructured":"Pan, J., Ng, S. M., Neubauer, S. & Rider, O. J. Phenotyping heart failure by cardiac magnetic resonance imaging of cardiac macro- and microscopic structure: state of the art review. Eur. Heart J. Cardiovasc. Imaging 24, 1302\u20131317 (2023).","journal-title":"Eur. Heart J. Cardiovasc. Imaging"},{"key":"1163_CR96","doi-asserted-by":"publisher","first-page":"57","DOI":"10.1002\/mrm.28964","volume":"87","author":"RS Tougaard","year":"2022","unstructured":"Tougaard, R. S. et al. Remodeling after myocardial infarction and effects of heart failure treatment investigated by hyperpolarized [1-13 C]pyruvate magnetic resonance spectroscopy. Magn. Reson. Med. 87, 57\u201369 (2022).","journal-title":"Magn. Reson. Med."},{"key":"1163_CR97","doi-asserted-by":"publisher","first-page":"725","DOI":"10.1161\/CIRCRESAHA.119.316260","volume":"126","author":"OJ Rider","year":"2020","unstructured":"Rider, O. J. et al. Noninvasive in vivo assessment of cardiac metabolism in the healthy and diabetic human heart using hyperpolarized 13C MRI. Circ. Res. 126, 725\u2013736 (2020).","journal-title":"Circ. Res."},{"key":"1163_CR98","doi-asserted-by":"publisher","first-page":"2324","DOI":"10.1056\/NEJMoa0806576","volume":"359","author":"JM Miller","year":"2008","unstructured":"Miller, J. M. et al. Diagnostic performance of coronary angiography by 64-row CT. N. Engl. J. Med. 359, 2324\u20132336 (2008).","journal-title":"N. Engl. J. Med."},{"key":"1163_CR99","doi-asserted-by":"publisher","first-page":"192","DOI":"10.1016\/j.jcct.2020.11.001","volume":"15","author":"J Narula","year":"2021","unstructured":"Narula, J. et al. SCCT 2021 expert consensus document on coronary computed tomographic angiography: a report of the society of cardiovascular computed tomography. J. Cardiovasc. Comput. Tomogr. 15, 192\u2013217 (2021).","journal-title":"J. Cardiovasc. Comput. Tomogr."},{"key":"1163_CR100","doi-asserted-by":"publisher","first-page":"1989","DOI":"10.1016\/j.jacc.2011.06.066","volume":"58","author":"BK Koo","year":"2011","unstructured":"Koo, B. K. et al. Diagnosis of ischemia-causing coronary stenoses by noninvasive fractional flow reserve computed from coronary computed tomographic angiograms. Results from the prospective multicenter DISCOVER-FLOW (diagnosis of ischemia-causing stenoses obtained via noninvasive fractional flow reserve) study. J. Am. Coll. Cardiol. 58, 1989\u20131997 (2011).","journal-title":"J. Am. Coll. Cardiol."},{"key":"1163_CR101","doi-asserted-by":"publisher","first-page":"881","DOI":"10.1161\/CIRCIMAGING.113.000297","volume":"6","author":"R Nakazato","year":"2013","unstructured":"Nakazato, R. et al. Noninvasive fractional flow reserve derived from computed tomography angiography for coronary lesions of intermediate stenosis severity: results from the DeFACTO study. Circ. Cardiovasc. Imaging 6, 881\u2013889 (2013).","journal-title":"Circ. Cardiovasc. Imaging"},{"key":"1163_CR102","doi-asserted-by":"publisher","first-page":"1145","DOI":"10.1016\/j.jacc.2013.11.043","volume":"63","author":"BL Norgaard","year":"2014","unstructured":"Norgaard, B. L. et al. Diagnostic performance of noninvasive fractional flow reserve derived from coronary computed tomography angiography in suspected coronary artery disease: the NXT trial (analysis of coronary blood flow using ct angiography: next steps). J. Am. Coll. Cardiol. 63, 1145\u20131155 (2014).","journal-title":"J. Am. Coll. Cardiol."},{"key":"1163_CR103","doi-asserted-by":"publisher","first-page":"5509","DOI":"10.1007\/s00330-023-09550-y","volume":"33","author":"O Sliwicka","year":"2023","unstructured":"Sliwicka, O. et al. Dynamic myocardial CT perfusion imaging-state of the art. Eur. Radiol. 33, 5509\u20135525 (2023).","journal-title":"Eur. Radiol."},{"key":"1163_CR104","doi-asserted-by":"publisher","first-page":"7062","DOI":"10.3390\/jcm12227062","volume":"12","author":"A Zdanowicz","year":"2023","unstructured":"Zdanowicz, A., Guzinski, M., Pula, M., Witkowska, A. & Reczuch, K. Dynamic CT myocardial perfusion: the role of functional evaluation in the diagnosis of coronary artery disease. J. Clin. Med. 12, 7062 (2023).","journal-title":"J. Clin. Med."},{"key":"1163_CR105","doi-asserted-by":"publisher","first-page":"1686","DOI":"10.1007\/s12350-021-02721-8","volume":"29","author":"M Panjer","year":"2022","unstructured":"Panjer, M., Dobrolinska, M., Wagenaar, N. R. L. & Slart, R. Diagnostic accuracy of dynamic CZT-SPECT in coronary artery disease. A systematic review and meta-analysis. J. Nucl. Cardiol. 29, 1686\u20131697 (2022).","journal-title":"J. Nucl. Cardiol."},{"key":"1163_CR106","first-page":"I22","volume":"84","author":"KL Gould","year":"1991","unstructured":"Gould, K. L. Clinical cardiac positron emission tomography: state of the art. Circulation 84, I22\u2013I36 (1991).","journal-title":"Circulation"},{"key":"1163_CR107","doi-asserted-by":"publisher","first-page":"1900","DOI":"10.1161\/01.CIR.95.7.1900","volume":"95","author":"JA Fallavollita","year":"1997","unstructured":"Fallavollita, J. A., Perry, B. J. & Canty, J. M. Jr. 18F-2-deoxyglucose deposition and regional flow in pigs with chronically dysfunctional myocardium. Evidence for transmural variations in chronic hibernating myocardium. Circulation 95, 1900\u20131909 (1997).","journal-title":"Circulation"},{"key":"1163_CR108","doi-asserted-by":"crossref","unstructured":"Schulz, R., Kappeler, C., Coenen, H., Bockisch, A. & Heusch, G. Positron emission tomography analysis of [1-11C] acetate kinetics in short-term hibernating myocardium. Circulation 97, 1009\u20131016.","DOI":"10.1161\/01.CIR.97.10.1009"},{"key":"1163_CR109","doi-asserted-by":"publisher","first-page":"1187","DOI":"10.1007\/s12350-016-0522-3","volume":"23","author":"V Dilsizian","year":"2016","unstructured":"Dilsizian, V. et al. ASNC imaging guidelines\/SNMMI procedure standard for positron emission tomography (PET) nuclear cardiology procedures. J. Nucl. Cardiol. 23, 1187\u20131226 (2016).","journal-title":"J. Nucl. Cardiol."},{"key":"1163_CR110","doi-asserted-by":"publisher","first-page":"13","DOI":"10.1136\/heartjnl-2013-303832","volume":"100","author":"RP Amier","year":"2014","unstructured":"Amier, R. P., Teunissen, P. F., Marques, K. M., Knaapen, P. & van Royen, N. Invasive measurement of coronary microvascular resistance in patients with acute myocardial infarction treated by primary PCI. Heart 100, 13\u201320 (2014).","journal-title":"Heart"},{"key":"1163_CR111","doi-asserted-by":"publisher","first-page":"177","DOI":"10.1016\/j.jacc.2010.04.012","volume":"56","author":"NH Pijls","year":"2010","unstructured":"Pijls, N. H. et al. Fractional flow reserve versus angiography for guiding percutaneous coronary intervention in patients with multivessel coronary artery disease: 2-year follow-up of the FAME (fractional flow reserve versus angiography for multivessel evaluation) study. J. Am. Coll. Cardiol. 56, 177\u2013184 (2010).","journal-title":"J. Am. Coll. Cardiol."},{"key":"1163_CR112","doi-asserted-by":"publisher","first-page":"16","DOI":"10.1016\/j.carrev.2024.12.011","volume":"71","author":"C Yang","year":"2025","unstructured":"Yang, C., Wong, C., Teradaa, K. & Tremmel, J. A. FFR, iFR, CFR, and IMR: results from clinical trials. Cardiovasc. Revasc. Med. 71, 16\u201321 (2025).","journal-title":"Cardiovasc. Revasc. Med."},{"key":"1163_CR113","doi-asserted-by":"publisher","first-page":"1395","DOI":"10.1007\/s10554-020-01831-7","volume":"36","author":"GL De Maria","year":"2020","unstructured":"De Maria, G. L. et al. Angiography-derived index of microcirculatory resistance as a novel, pressure-wire-free tool to assess coronary microcirculation in ST elevation myocardial infarction. Int. J. Cardiovasc. Imaging 36, 1395\u20131406 (2020).","journal-title":"Int. J. Cardiovasc. Imaging"},{"key":"1163_CR114","doi-asserted-by":"publisher","DOI":"10.1016\/j.jjcc.2025.03.001","author":"M Noguchi","year":"2025","unstructured":"Noguchi, M. & Dohi, T. Recent advances and clinical implications of intravascular imaging. J. Cardiol. https:\/\/doi.org\/10.1016\/j.jjcc.2025.03.001 (2025).","journal-title":"J. Cardiol."},{"key":"1163_CR115","doi-asserted-by":"publisher","first-page":"985","DOI":"10.1016\/S0140-6736(21)00249-X","volume":"397","author":"D Erlinge","year":"2021","unstructured":"Erlinge, D. et al. Identification of vulnerable plaques and patients by intracoronary near-infrared spectroscopy and ultrasound (PROSPECT II): a prospective natural history study. Lancet 397, 985\u2013995 (2021).","journal-title":"Lancet"},{"key":"1163_CR116","doi-asserted-by":"publisher","first-page":"1919","DOI":"10.1172\/JCI119722","volume":"100","author":"HE Botker","year":"1997","unstructured":"Botker, H. E., Moller, N., Schmitz, O., Bagger, J. P. & Nielsen, T. T. Myocardial insulin resistance in patients with syndrome X. J. Clin. Invest. 100, 1919\u20131927 (1997).","journal-title":"J. Clin. Invest."},{"key":"1163_CR117","doi-asserted-by":"publisher","first-page":"732","DOI":"10.1016\/j.healun.2022.01.1376","volume":"41","author":"ED Lichscheidt","year":"2022","unstructured":"Lichscheidt, E. D. et al. Abnormal mitochondrial function and morphology in heart transplanted patients with cardiac allograft vasculopathy. J. Heart Lung Transpl. 41, 732\u2013741 (2022).","journal-title":"J. Heart Lung Transpl."},{"key":"1163_CR118","doi-asserted-by":"publisher","first-page":"1246","DOI":"10.1002\/ehf2.15133","volume":"12","author":"J Borger","year":"2024","unstructured":"Borger, J. et al. Myocardial inflammation is associated with impaired mitochondrial oxidative capacity in ischaemic cardiomyopathy. Esc. Heart Fail. 12, 1246\u20131255 (2024).","journal-title":"Esc. Heart Fail."},{"key":"1163_CR119","doi-asserted-by":"publisher","first-page":"2339","DOI":"10.1161\/01.CIR.103.19.2339","volume":"103","author":"J Herrmann","year":"2001","unstructured":"Herrmann, J. et al. Abnormal coronary flow velocity reserve after coronary intervention is associated with cardiac marker elevation. Circulation 103, 2339\u20132345 (2001).","journal-title":"Circulation"},{"key":"1163_CR120","doi-asserted-by":"publisher","first-page":"1805","DOI":"10.1161\/CIRCULATIONAHA.119.041595","volume":"140","author":"H Rahman","year":"2019","unstructured":"Rahman, H. et al. Coronary microvascular dysfunction is associated with myocardial ischemia and abnormal coronary perfusion during exercise. Circulation 140, 1805\u20131816 (2019).","journal-title":"Circulation"},{"key":"1163_CR121","doi-asserted-by":"publisher","first-page":"1101","DOI":"10.1093\/eurheartj\/eht513","volume":"35","author":"F Crea","year":"2014","unstructured":"Crea, F., Camici, P. G. & Bairey Merz, C. N. Coronary microvascular dysfunction: an update. Eur. Heart J. 35, 1101\u20131111 (2014).","journal-title":"Eur. Heart J."},{"key":"1163_CR122","doi-asserted-by":"publisher","first-page":"756","DOI":"10.1093\/cvr\/cvaa002","volume":"116","author":"O Sorop","year":"2020","unstructured":"Sorop, O. et al. Experimental animal models of coronary microvascular dysfunction. Cardiovasc. Res. 116, 756\u2013770 (2020).","journal-title":"Cardiovasc. Res."},{"key":"1163_CR123","doi-asserted-by":"publisher","first-page":"370","DOI":"10.1161\/01.CIR.71.2.370","volume":"71","author":"JM Canty Jr.","year":"1985","unstructured":"Canty, J. M. Jr. & Klocke, F. J. Reduced regional myocardial perfusion in the presence of pharmacologic vasodilator reserve. Circulation 71, 370\u2013377 (1985).","journal-title":"Circulation"},{"key":"1163_CR124","doi-asserted-by":"publisher","first-page":"482","DOI":"10.1161\/01.CIR.75.2.482","volume":"75","author":"G Heusch","year":"1987","unstructured":"Heusch, G., Guth, B. D., Seitelberger, R. & Ross, J. Jr. Attenuation of exercise-induced myocardial ischemia in dogs with recruitment of coronary vasodilator reserve by nifedipine. Circulation 75, 482\u2013490 (1987).","journal-title":"Circulation"},{"key":"1163_CR125","doi-asserted-by":"publisher","first-page":"1541","DOI":"10.1016\/j.jacc.2021.08.017","volume":"78","author":"B De Bruyne","year":"2021","unstructured":"De Bruyne, B. et al. Microvascular resistance reserve for assessment of coronary microvascular function: JACC technology corner. J. Am. Coll. Cardiol. 78, 1541\u20131549 (2021).","journal-title":"J. Am. Coll. Cardiol."},{"key":"1163_CR126","doi-asserted-by":"publisher","first-page":"2862","DOI":"10.1093\/eurheartj\/ehad378","volume":"44","author":"CKM Boerhout","year":"2023","unstructured":"Boerhout, C. K. M. et al. Microvascular resistance reserve: diagnostic and prognostic performance in the ILIAS registry. Eur. Heart J. 44, 2862\u20132869 (2023).","journal-title":"Eur. Heart J."},{"key":"1163_CR127","doi-asserted-by":"publisher","first-page":"424","DOI":"10.1093\/eurheartj\/ehae604","volume":"46","author":"LD Rasmussen","year":"2024","unstructured":"Rasmussen, L. D. et al. Microvascular resistance reserve: impact on health status and myocardial perfusion after revascularization in chronic coronary syndrome. Eur. Heart J. 46, 424\u2013435 (2024).","journal-title":"Eur. Heart J."},{"key":"1163_CR128","doi-asserted-by":"publisher","first-page":"30","DOI":"10.1038\/nrcardio.2016.163","volume":"14","author":"J Hartupee","year":"2017","unstructured":"Hartupee, J. & Mann, D. L. Neurohormonal activation in heart failure with reduced ejection fraction. Nat. Rev. Cardiol. 14, 30\u201338 (2017).","journal-title":"Nat. Rev. Cardiol."},{"key":"1163_CR129","doi-asserted-by":"publisher","first-page":"91","DOI":"10.1016\/j.ijcard.2019.08.040","volume":"296","author":"G Vergaro","year":"2019","unstructured":"Vergaro, G. et al. Sympathetic and renin-angiotensin-aldosterone system activation in heart failure with preserved, mid-range and reduced ejection fraction. Int. J. Cardiol. 296, 91\u201397 (2019).","journal-title":"Int. J. Cardiol."},{"key":"1163_CR130","doi-asserted-by":"publisher","first-page":"2437","DOI":"10.1093\/cvr\/cvab279","volume":"118","author":"PS Russell","year":"2022","unstructured":"Russell, P. S. et al. Lymphatic contractile function: a comprehensive review of drug effects and potential clinical application. Cardiovasc. Res. 118, 2437\u20132457 (2022).","journal-title":"Cardiovasc. Res."},{"key":"1163_CR131","doi-asserted-by":"publisher","first-page":"1964","DOI":"10.1056\/NEJMra1703100","volume":"377","author":"DH Ellison","year":"2017","unstructured":"Ellison, D. H. & Felker, G. M. Diuretic treatment in heart failure. N. Engl. J. Med. 377, 1964\u20131975 (2017).","journal-title":"N. Engl. J. Med."},{"key":"1163_CR132","doi-asserted-by":"publisher","first-page":"149","DOI":"10.1016\/S0167-5273(01)00600-3","volume":"82","author":"R Faris","year":"2002","unstructured":"Faris, R. et al. Current evidence supporting the role of diuretics in heart failure: a meta analysis of randomised controlled trials. Int. J. Cardiol. 82, 149\u2013158 (2002).","journal-title":"Int. J. Cardiol."},{"key":"1163_CR133","doi-asserted-by":"publisher","first-page":"988","DOI":"10.1016\/S0008-6363(96)00134-4","volume":"32","author":"TP Dormans","year":"1996","unstructured":"Dormans, T. P., Pickkers, P., Russel, F. G. & Smits, P. Vascular effects of loop diuretics. Cardiovasc. Res. 32, 988\u2013997 (1996).","journal-title":"Cardiovasc. Res."},{"key":"1163_CR134","doi-asserted-by":"publisher","first-page":"1847","DOI":"10.1161\/01.CIR.96.6.1847","volume":"96","author":"P Pickkers","year":"1997","unstructured":"Pickkers, P. et al. Direct vascular effects of furosemide in humans. Circulation 96, 1847\u20131852 (1997).","journal-title":"Circulation"},{"key":"1163_CR135","doi-asserted-by":"publisher","first-page":"537","DOI":"10.1161\/HYPERTENSIONAHA.118.11065","volume":"72","author":"G Jia","year":"2018","unstructured":"Jia, G., Aroor, A. R., Hill, M. A. & Sowers, J. R. Role of renin-angiotensin-aldosterone system activation in promoting cardiovascular fibrosis and stiffness. Hypertension 72, 537\u2013548 (2018).","journal-title":"Hypertension"},{"key":"1163_CR136","doi-asserted-by":"publisher","first-page":"145","DOI":"10.1016\/0014-2999(91)90812-5","volume":"205","author":"T Uchida","year":"1991","unstructured":"Uchida, T. et al. Anti-aldosteronergic effect of torasemide. Eur. J. Pharmacol. 205, 145\u2013150 (1991).","journal-title":"Eur. J. Pharmacol."},{"key":"1163_CR137","doi-asserted-by":"publisher","first-page":"214","DOI":"10.1001\/jama.2022.23924","volume":"329","author":"RJ Mentz","year":"2023","unstructured":"Mentz, R. J. et al. Effect of torsemide vs furosemide after discharge on all-cause mortality in patients hospitalized with heart failure: the TRANSFORM-HF randomized clinical trial. JAMA 329, 214\u2013223 (2023).","journal-title":"JAMA"},{"key":"1163_CR138","doi-asserted-by":"publisher","first-page":"157","DOI":"10.1016\/j.jchf.2019.09.012","volume":"8","author":"ZL Cox","year":"2020","unstructured":"Cox, Z. L., Hung, R., Lenihan, D. J. & Testani, J. M. Diuretic strategies for loop diuretic resistance in acute heart failure: the 3t trial. JACC Heart Fail. 8, 157\u2013168 (2020).","journal-title":"JACC Heart Fail."},{"key":"1163_CR139","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/j.jchf.2015.06.017","volume":"4","author":"LF Buckley","year":"2016","unstructured":"Buckley, L. F. et al. Intravenous diuretic therapy for the management of heart failure and volume overload in a multidisciplinary outpatient unit. JACC Heart Fail. 4, 1\u20138 (2016).","journal-title":"JACC Heart Fail."},{"key":"1163_CR140","doi-asserted-by":"publisher","first-page":"1178","DOI":"10.1016\/j.jacc.2019.12.059","volume":"75","author":"GM Felker","year":"2020","unstructured":"Felker, G. M., Ellison, D. H., Mullens, W., Cox, Z. L. & Testani, J. M. Diuretic therapy for patients with heart failure: JACC state-of-the-art review. J. Am. Coll. Cardiol. 75, 1178\u20131195 (2020).","journal-title":"J. Am. Coll. Cardiol."},{"key":"1163_CR141","doi-asserted-by":"publisher","first-page":"12","DOI":"10.1159\/000164149","volume":"113","author":"WF Peacock","year":"2009","unstructured":"Peacock, W. F. et al. Impact of intravenous loop diuretics on outcomes of patients hospitalized with acute decompensated heart failure: insights from the ADHERE registry. Cardiology 113, 12\u201319 (2009).","journal-title":"Cardiology"},{"key":"1163_CR142","doi-asserted-by":"publisher","first-page":"797","DOI":"10.1056\/NEJMoa1005419","volume":"364","author":"GM Felker","year":"2011","unstructured":"Felker, G. M. et al. Diuretic strategies in patients with acute decompensated heart failure. N. Engl. J. Med. 364, 797\u2013805 (2011).","journal-title":"N. Engl. J. Med."},{"key":"1163_CR143","doi-asserted-by":"publisher","first-page":"1383","DOI":"10.1056\/NEJMoa1313731","volume":"370","author":"B Pitt","year":"2014","unstructured":"Pitt, B. et al. Spironolactone for heart failure with preserved ejection fraction. N. Engl. J. Med. 370, 1383\u20131392 (2014).","journal-title":"N. Engl. J. Med."},{"key":"1163_CR144","doi-asserted-by":"publisher","first-page":"34","DOI":"10.1161\/CIRCULATIONAHA.114.013255","volume":"131","author":"MA Pfeffer","year":"2015","unstructured":"Pfeffer, M. A. et al. Regional variation in patients and outcomes in the treatment of preserved cardiac function heart failure with an aldosterone antagonist (TOPCAT) trial. Circulation 131, 34\u201342 (2015).","journal-title":"Circulation"},{"key":"1163_CR145","doi-asserted-by":"publisher","first-page":"1119","DOI":"10.1016\/S0140-6736(24)01733-1","volume":"404","author":"PS Jhund","year":"2024","unstructured":"Jhund, P. S. et al. Mineralocorticoid receptor antagonists in heart failure: an individual patient level meta-analysis. Lancet 404, 1119\u20131131 (2024).","journal-title":"Lancet"},{"key":"1163_CR146","doi-asserted-by":"publisher","first-page":"2436","DOI":"10.1681\/ASN.2015070815","volume":"27","author":"AS Terker","year":"2016","unstructured":"Terker, A. S. et al. Direct and indirect mineralocorticoid effects determine distal salt transport. J. Am. Soc. Nephrol. 27, 2436\u20132445 (2016).","journal-title":"J. Am. Soc. Nephrol."},{"key":"1163_CR147","doi-asserted-by":"publisher","first-page":"1429","DOI":"10.1038\/nm.2891","volume":"18","author":"A McCurley","year":"2012","unstructured":"McCurley, A. et al. Direct regulation of blood pressure by smooth muscle cell mineralocorticoid receptors. Nat. Med. 18, 1429\u20131433 (2012).","journal-title":"Nat. Med."},{"key":"1163_CR148","doi-asserted-by":"publisher","first-page":"206","DOI":"10.1161\/CIRCRESAHA.116.302706","volume":"116","author":"CM Ferrario","year":"2015","unstructured":"Ferrario, C. M. & Schiffrin, E. L. Role of mineralocorticoid receptor antagonists in cardiovascular disease. Circ. Res. 116, 206\u2013213 (2015).","journal-title":"Circ. Res."},{"key":"1163_CR149","doi-asserted-by":"publisher","first-page":"2435","DOI":"10.1161\/CIRCULATIONAHA.107.722009","volume":"116","author":"ML Ambroisine","year":"2007","unstructured":"Ambroisine, M. L. et al. Aldosterone-induced coronary dysfunction in transgenic mice involves the calcium-activated potassium (BKCa) channels of vascular smooth muscle cells. Circulation 116, 2435\u20132443 (2007).","journal-title":"Circulation"},{"key":"1163_CR150","doi-asserted-by":"publisher","first-page":"1008","DOI":"10.1161\/HYPERTENSIONAHA.123.21358","volume":"81","author":"ND Camarda","year":"2024","unstructured":"Camarda, N. D., Ibarrola, J., Biwer, L. A. & Jaffe, I. Z. Mineralocorticoid receptors in vascular smooth muscle: blood pressure and beyond. Hypertension 81, 1008\u20131020 (2024).","journal-title":"Hypertension"},{"key":"1163_CR151","doi-asserted-by":"publisher","first-page":"594","DOI":"10.1161\/01.CIR.101.6.594","volume":"101","author":"CA Farquharson","year":"2000","unstructured":"Farquharson, C. A. & Struthers, A. D. Spironolactone increases nitric oxide bioactivity, improves endothelial vasodilator dysfunction, and suppresses vascular angiotensin I\/angiotensin II conversion in patients with chronic heart failure. Circulation 101, 594\u2013597 (2000).","journal-title":"Circulation"},{"key":"1163_CR152","doi-asserted-by":"publisher","first-page":"1050","DOI":"10.1161\/01.HYP.0000248135.97380.76","volume":"48","author":"JM Luther","year":"2006","unstructured":"Luther, J. M. et al. Angiotensin II induces interleukin-6 in humans through a mineralocorticoid receptor-dependent mechanism. Hypertension 48, 1050\u20131057 (2006).","journal-title":"Hypertension"},{"key":"1163_CR153","doi-asserted-by":"publisher","first-page":"87","DOI":"10.1016\/j.imlet.2003.11.008","volume":"91","author":"PR Hansen","year":"2004","unstructured":"Hansen, P. R., Rieneck, K. & Bendtzen, K. Spironolactone inhibits production of proinflammatory cytokines by human mononuclear cells. Immunol. Lett. 91, 87\u201391 (2004).","journal-title":"Immunol. Lett."},{"key":"1163_CR154","doi-asserted-by":"publisher","first-page":"46","DOI":"10.1038\/sj.bjp.0706700","volume":"148","author":"SU Sonder","year":"2006","unstructured":"Sonder, S. U., Mikkelsen, M., Rieneck, K., Hedegaard, C. J. & Bendtzen, K. Effects of spironolactone on human blood mononuclear cells: mineralocorticoid receptor independent effects on gene expression and late apoptosis induction. Br. J. Pharmacol. 148, 46\u201353 (2006).","journal-title":"Br. J. Pharmacol."},{"key":"1163_CR155","doi-asserted-by":"publisher","first-page":"672","DOI":"10.1016\/j.jacc.2019.04.067","volume":"74","author":"P Joseph","year":"2019","unstructured":"Joseph, P., Swedberg, K., Leong, D. P. & Yusuf, S. The evolution of \u03b2-blockers in coronary artery disease and heart failure (part 1\/5). J. Am. Coll. Cardiol. 74, 672\u2013682 (2019).","journal-title":"J. Am. Coll. Cardiol."},{"key":"1163_CR156","doi-asserted-by":"publisher","first-page":"1372","DOI":"10.1056\/NEJMoa2401479","volume":"390","author":"T Yndigegn","year":"2024","unstructured":"Yndigegn, T. et al. Beta-blockers after myocardial infarction and preserved ejection fraction. N. Engl. J. Med. 390, 1372\u20131381 (2024).","journal-title":"N. Engl. J. Med."},{"key":"1163_CR157","doi-asserted-by":"publisher","DOI":"10.1001\/jamanetworkopen.2019.16598","volume":"2","author":"DN Silverman","year":"2019","unstructured":"Silverman, D. N. et al. Association of \u03b2-blocker use with heart failure hospitalizations and cardiovascular disease mortality among patients with heart failure with a preserved ejection fraction: a secondary analysis of the TOPCAT trial. JAMA Netw. Open 2, e1916598 (2019).","journal-title":"JAMA Netw. Open"},{"key":"1163_CR158","doi-asserted-by":"publisher","first-page":"2042","DOI":"10.1016\/j.jacc.2021.08.073","volume":"78","author":"P Palau","year":"2021","unstructured":"Palau, P. et al. Effect of \u03b2-blocker withdrawal on functional capacity in heart failure and preserved ejection fraction. J. Am. Coll. Cardiol. 78, 2042\u20132056 (2021).","journal-title":"J. Am. Coll. Cardiol."},{"key":"1163_CR159","doi-asserted-by":"publisher","first-page":"3027","DOI":"10.1093\/eurheartj\/ehp341","volume":"30","author":"R Wachter","year":"2009","unstructured":"Wachter, R. et al. Blunted frequency-dependent upregulation of cardiac output is related to impaired relaxation in diastolic heart failure. Eur. Heart J. 30, 3027\u20133036 (2009).","journal-title":"Eur. Heart J."},{"key":"1163_CR160","doi-asserted-by":"publisher","first-page":"2885","DOI":"10.1016\/j.jacc.2017.04.001","volume":"69","author":"D Kotecha","year":"2017","unstructured":"Kotecha, D. et al. Heart rate and rhythm and the benefit of beta-blockers in patients with heart failure. J. Am. Coll. Cardiol. 69, 2885\u20132896 (2017).","journal-title":"J. Am. Coll. Cardiol."},{"key":"1163_CR161","doi-asserted-by":"publisher","first-page":"1198","DOI":"10.1161\/CIRCULATIONAHA.104.532960","volume":"112","author":"C Dessy","year":"2005","unstructured":"Dessy, C. et al. Endothelial \u03b23-adrenoreceptors mediate nitric oxide-dependent vasorelaxation of coronary microvessels in response to the third-generation \u03b2-blocker nebivolol. Circulation 112, 1198\u20131205 (2005).","journal-title":"Circulation"},{"key":"1163_CR162","doi-asserted-by":"publisher","first-page":"1151","DOI":"10.1161\/01.RES.65.4.1151","volume":"65","author":"IT Mak","year":"1989","unstructured":"Mak, I. T., Arroyo, C. M. & Weglicki, W. B. Inhibition of sarcolemmal carbon-centered free radical formation by propranolol. Circ. Res. 65, 1151\u20131156 (1989).","journal-title":"Circ. Res."},{"key":"1163_CR163","doi-asserted-by":"publisher","first-page":"24","DOI":"10.1093\/eurheartj\/17.suppl_B.24","volume":"17","author":"GZ Feuerstein","year":"1996","unstructured":"Feuerstein, G. Z. & Ruffolo, R. R. Jr. Carvedilol, a novel vasodilating beta-blocker with the potential for cardiovascular organ protection. Eur. Heart J. 17, 24\u201329 (1996).","journal-title":"Eur. Heart J."},{"key":"1163_CR164","doi-asserted-by":"publisher","first-page":"391","DOI":"10.1016\/S0735-1097(97)00494-4","volume":"31","author":"T Tsutamoto","year":"1998","unstructured":"Tsutamoto, T. et al. Interleukin-6 spillover in the peripheral circulation increases with the severity of heart failure, and the high plasma level of interleukin-6 is an important prognostic predictor in patients with congestive heart failure. J. Am. Coll. Cardiol. 31, 391\u2013398 (1998).","journal-title":"J. Am. Coll. Cardiol."},{"key":"1163_CR165","doi-asserted-by":"publisher","first-page":"140","DOI":"10.1016\/j.jjcc.2019.07.011","volume":"75","author":"S Toyoda","year":"2020","unstructured":"Toyoda, S. et al. Effects of carvedilol vs bisoprolol on inflammation and oxidative stress in patients with chronic heart failure. J. Cardiol. 75, 140\u2013147 (2020).","journal-title":"J. Cardiol."},{"key":"1163_CR166","doi-asserted-by":"publisher","first-page":"430","DOI":"10.1016\/S0008-6363(00)00253-4","volume":"49","author":"BR Brehm","year":"2001","unstructured":"Brehm, B. R. et al. Effects of nebivolol on proliferation and apoptosis of human coronary artery smooth muscle and endothelial cells. Cardiovasc. Res. 49, 430\u2013439 (2001).","journal-title":"Cardiovasc. Res."},{"key":"1163_CR167","doi-asserted-by":"publisher","first-page":"1589","DOI":"10.1038\/sj.bjp.0707673","volume":"153","author":"G Heusch","year":"2008","unstructured":"Heusch, G. Heart rate in the pathophysiology of coronary blood flow and myocardial ischaemia: benefit from selective bradycardic agents. Br. J. Pharmacol. 153, 1589\u20131601 (2008).","journal-title":"Br. J. Pharmacol."},{"key":"1163_CR168","doi-asserted-by":"publisher","first-page":"436","DOI":"10.1161\/01.RES.62.3.436","volume":"62","author":"R Seitelberger","year":"1988","unstructured":"Seitelberger, R. et al. Intracoronary alpha 2-adrenergic receptor blockade attenuates ischemia in conscious dogs during exercise. Circ. Res. 62, 436\u2013442 (1988).","journal-title":"Circ. Res."},{"key":"1163_CR169","doi-asserted-by":"publisher","first-page":"875","DOI":"10.1016\/S0140-6736(10)61198-1","volume":"376","author":"K Swedberg","year":"2010","unstructured":"Swedberg, K. et al. Ivabradine and outcomes in chronic heart failure (SHIFT): a randomised placebo-controlled study. Lancet 376, 875\u2013885 (2010).","journal-title":"Lancet"},{"key":"1163_CR170","doi-asserted-by":"publisher","first-page":"2377","DOI":"10.1161\/CIRCULATIONAHA.107.746537","volume":"117","author":"F Custodis","year":"2008","unstructured":"Custodis, F. et al. Heart rate reduction by ivabradine reduces oxidative stress, improves endothelial function, and prevents atherosclerosis in apolipoprotein E-deficient mice. Circulation 117, 2377\u20132387 (2008).","journal-title":"Circulation"},{"key":"1163_CR171","doi-asserted-by":"publisher","first-page":"2265","DOI":"10.1093\/eurheartj\/ehn337","volume":"29","author":"G Heusch","year":"2008","unstructured":"Heusch, G. et al. Improvement of regional myocardial blood flow and function and reduction of infarct size with ivabradine: protection beyond heart rate reduction. Eur. Heart J. 29, 2265\u20132275 (2008).","journal-title":"Eur. Heart J."},{"key":"1163_CR172","doi-asserted-by":"publisher","DOI":"10.1161\/CIRCHEARTFAILURE.116.003529","volume":"10","author":"H Burnett","year":"2017","unstructured":"Burnett, H. et al. Thirty years of evidence on the efficacy of drug treatments for chronic heart failure with reduced ejection fraction: a network meta-analysis. Circ. Heart Fail. 10, e003529 (2017).","journal-title":"Circ. Heart Fail."},{"key":"1163_CR173","doi-asserted-by":"publisher","first-page":"2982","DOI":"10.1093\/eurheartj\/ehad344","volume":"44","author":"M Vaduganathan","year":"2023","unstructured":"Vaduganathan, M. et al. Sacubitril\/valsartan in heart failure with mildly reduced or preserved ejection fraction: a pre-specified participant-level pooled analysis of PARAGLIDE-HF and PARAGON-HF. Eur. Heart J. 44, 2982\u20132993 (2023).","journal-title":"Eur. Heart J."},{"key":"1163_CR174","doi-asserted-by":"publisher","first-page":"e263","DOI":"10.1016\/j.jacc.2021.12.012","volume":"79","author":"PA Heidenreich","year":"2022","unstructured":"Heidenreich, P. A. et al. 2022 AHA\/ACC\/HFSA guideline for the management of heart failure: a report of the American College of Cardiology\/American Heart Association Joint Committee on Clinical Practice Guidelines. J. Am. Coll. Cardiol. 79, e263\u2013e421 (2022).","journal-title":"J. Am. Coll. Cardiol."},{"key":"1163_CR175","doi-asserted-by":"publisher","first-page":"3599","DOI":"10.1093\/eurheartj\/ehab368","volume":"42","author":"TA McDonagh","year":"2021","unstructured":"McDonagh, T. A. et al. 2021 ESC guidelines for the diagnosis and treatment of acute and chronic heart failure. Eur. Heart J. 42, 3599\u20133726 (2021).","journal-title":"Eur. Heart J."},{"key":"1163_CR176","doi-asserted-by":"publisher","first-page":"125","DOI":"10.1038\/nrcardio.2012.196","volume":"10","author":"CC Lang","year":"2013","unstructured":"Lang, C. C. & Struthers, A. D. Targeting the renin-angiotensin-aldosterone system in heart failure. Nat. Rev. Cardiol. 10, 125\u2013134 (2013).","journal-title":"Nat. Rev. Cardiol."},{"key":"1163_CR177","doi-asserted-by":"publisher","first-page":"1115","DOI":"10.1161\/01.CIR.95.5.1115","volume":"95","author":"B Hornig","year":"1997","unstructured":"Hornig, B., Kohler, C. & Drexler, H. Role of bradykinin in mediating vascular effects of angiotensin-converting enzyme inhibitors in humans. Circulation 95, 1115\u20131118 (1997).","journal-title":"Circulation"},{"key":"1163_CR178","doi-asserted-by":"publisher","first-page":"441","DOI":"10.1161\/CIRCRESAHA.107.148338","volume":"101","author":"S Heeneman","year":"2007","unstructured":"Heeneman, S., Sluimer, J. C. & Daemen, M. J. Angiotensin-converting enzyme and vascular remodeling. Circ. Res. 101, 441\u2013454 (2007).","journal-title":"Circ. Res."},{"key":"1163_CR179","doi-asserted-by":"publisher","first-page":"1223","DOI":"10.1161\/01.CIR.100.11.1223","volume":"100","author":"PE Tummala","year":"1999","unstructured":"Tummala, P. E. et al. Angiotensin II induces vascular cell adhesion molecule-1 expression in rat vasculature: a potential link between the renin-angiotensin system and atherosclerosis. Circulation 100, 1223\u20131229 (1999).","journal-title":"Circulation"},{"key":"1163_CR180","doi-asserted-by":"publisher","first-page":"383","DOI":"10.1016\/j.amjcard.2012.03.034","volume":"110","author":"H Makani","year":"2012","unstructured":"Makani, H. et al. Meta-analysis of randomized trials of angioedema as an adverse event of renin-angiotensin system inhibitors. Am. J. Cardiol. 110, 383\u2013391 (2012).","journal-title":"Am. J. Cardiol."},{"key":"1163_CR181","doi-asserted-by":"publisher","first-page":"289","DOI":"10.1161\/HYPERTENSIONAHA.116.06591","volume":"68","author":"NP Rudemiller","year":"2016","unstructured":"Rudemiller, N. P. & Crowley, S. D. Interactions between the immune and the renin-angiotensin systems in hypertension. Hypertension 68, 289\u2013296 (2016).","journal-title":"Hypertension"},{"key":"1163_CR182","doi-asserted-by":"publisher","first-page":"88","DOI":"10.1016\/j.jacbts.2022.05.010","volume":"8","author":"B Bozkurt","year":"2023","unstructured":"Bozkurt, B. et al. Neprilysin Inhibitors in heart failure: the science, mechanism of action, clinical studies, and unanswered questions. JACC Basic Transl. Sci. 8, 88\u2013105 (2023).","journal-title":"JACC Basic Transl. Sci."},{"key":"1163_CR183","doi-asserted-by":"publisher","DOI":"10.1161\/JAHA.123.032641","volume":"13","author":"IN Schellinger","year":"2024","unstructured":"Schellinger, I. N. et al. Angiotensin receptor-neprilysin inhibition (sacubitril\/valsartan) reduces structural arterial stiffness in middle-aged mice. J. Am. Heart Assoc. 13, e032641 (2024).","journal-title":"J. Am. Heart Assoc."},{"key":"1163_CR184","doi-asserted-by":"publisher","first-page":"1077","DOI":"10.1001\/jama.2019.12843","volume":"322","author":"AS Desai","year":"2019","unstructured":"Desai, A. S. et al. Effect of sacubitril-valsartan vs enalapril on aortic stiffness in patients with heart failure and reduced ejection fraction: a randomized clinical trial. JAMA 322, 1077\u20131084 (2019).","journal-title":"JAMA"},{"key":"1163_CR185","doi-asserted-by":"publisher","first-page":"443","DOI":"10.1093\/cvr\/cvae047","volume":"120","author":"A Preda","year":"2024","unstructured":"Preda, A. et al. SGLT2 inhibitors: from glucose-lowering to cardiovascular benefits. Cardiovasc. Res. 120, 443\u2013460 (2024).","journal-title":"Cardiovasc. Res."},{"key":"1163_CR186","doi-asserted-by":"publisher","first-page":"757","DOI":"10.1016\/S0140-6736(22)01429-5","volume":"400","author":"M Vaduganathan","year":"2022","unstructured":"Vaduganathan, M. et al. SGLT-2 inhibitors in patients with heart failure: a comprehensive meta-analysis of five randomised controlled trials. Lancet 400, 757\u2013767 (2022).","journal-title":"Lancet"},{"key":"1163_CR187","doi-asserted-by":"publisher","DOI":"10.1126\/science.1260419","volume":"347","author":"M Uhlen","year":"2015","unstructured":"Uhlen, M. et al. Proteomics. Tissue-based map of the human proteome. Science 347, 1260419 (2015).","journal-title":"Science"},{"key":"1163_CR188","doi-asserted-by":"publisher","first-page":"371","DOI":"10.1016\/j.jacc.2023.10.030","volume":"83","author":"M Packer","year":"2024","unstructured":"Packer, M. Hyperuricemia and gout reduction by SGLT2 inhibitors in diabetes and heart failure: JACC review topic of the week. J. Am. Coll. Cardiol. 83, 371\u2013381 (2024).","journal-title":"J. Am. Coll. Cardiol."},{"key":"1163_CR189","doi-asserted-by":"publisher","first-page":"1383","DOI":"10.1161\/CIRCULATIONAHA.122.061732","volume":"146","author":"M Packer","year":"2022","unstructured":"Packer, M. Critical reanalysis of the mechanisms underlying the cardiorenal benefits of SGLT2 inhibitors and reaffirmation of the nutrient deprivation signaling\/autophagy hypothesis. Circulation 146, 1383\u20131405 (2022).","journal-title":"Circulation"},{"key":"1163_CR190","doi-asserted-by":"publisher","first-page":"229","DOI":"10.1161\/CIRCRESAHA.124.324708","volume":"136","author":"MV Basalay","year":"2025","unstructured":"Basalay, M. V. et al. SGLT2 inhibition induces cardioprotection by increasing parasympathetic activity. Circ. Res. 136, 229\u2013231 (2025).","journal-title":"Circ. Res."},{"key":"1163_CR191","doi-asserted-by":"publisher","first-page":"335","DOI":"10.1016\/j.redox.2017.12.019","volume":"15","author":"H Zhou","year":"2018","unstructured":"Zhou, H. et al. Empagliflozin rescues diabetic myocardial microvascular injury via AMPK-mediated inhibition of mitochondrial fission. Redox Biol. 15, 335\u2013346 (2018).","journal-title":"Redox Biol."},{"key":"1163_CR192","doi-asserted-by":"publisher","first-page":"2237","DOI":"10.1161\/ATVBAHA.121.316256","volume":"41","author":"S Kraler","year":"2021","unstructured":"Kraler, S. et al. Resilience of the internal mammary artery to atherogenesis: shifting from risk to resistance to address unmet needs. Arterioscler. Thromb. Vasc. Biol. 41, 2237\u20132251 (2021).","journal-title":"Arterioscler. Thromb. Vasc. Biol."},{"key":"1163_CR193","doi-asserted-by":"publisher","DOI":"10.1093\/cvr\/cvae257","author":"A Mroueh","year":"2024","unstructured":"Mroueh, A. et al. SGLT2 expression in human vasculature and heart correlates with low-grade inflammation and causes eNOS-NO\/ROS imbalance. Cardiovasc. Res. https:\/\/doi.org\/10.1093\/cvr\/cvae257 (2024).","journal-title":"Cardiovasc. Res."},{"key":"1163_CR194","doi-asserted-by":"publisher","first-page":"1633","DOI":"10.1161\/HYPERTENSIONAHA.122.19586","volume":"79","author":"P Mone","year":"2022","unstructured":"Mone, P. et al. SGLT2 inhibition via empagliflozin improves endothelial function and reduces mitochondrial oxidative stress: insights from frail hypertensive and diabetic patients. Hypertension 79, 1633\u20131643 (2022).","journal-title":"Hypertension"},{"key":"1163_CR195","doi-asserted-by":"publisher","first-page":"865","DOI":"10.33594\/000000178","volume":"53","author":"L Uthman","year":"2019","unstructured":"Uthman, L. et al. Empagliflozin and dapagliflozin reduce ROS generation and restore NO bioavailability in tumor necrosis factor \u03b1-stimulated human coronary arterial endothelial cells. Cell. Physiol. Biochem. 53, 865\u2013886 (2019).","journal-title":"Cell. Physiol. Biochem."},{"key":"1163_CR196","doi-asserted-by":"publisher","first-page":"729","DOI":"10.1161\/HYPERTENSIONAHA.120.16466","volume":"77","author":"A De Stefano","year":"2021","unstructured":"De Stefano, A. et al. Mechanisms of SGLT2 (sodium-glucose transporter type 2) inhibition-induced relaxation in arteries from human visceral adipose tissue. Hypertension 77, 729\u2013738 (2021).","journal-title":"Hypertension"},{"key":"1163_CR197","doi-asserted-by":"publisher","DOI":"10.1016\/j.cellsig.2020.109825","volume":"77","author":"S Sukhanov","year":"2021","unstructured":"Sukhanov, S. et al. The SGLT2 inhibitor empagliflozin attenuates interleukin-17A-induced human aortic smooth muscle cell proliferation and migration by targeting TRAF3IP2\/ROS\/NLRP3\/Caspase-1-dependent IL-1\u03b2 and IL-18 secretion. Cell. Signal. 77, 109825 (2021).","journal-title":"Cell. Signal."},{"key":"1163_CR198","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-020-15983-6","volume":"11","author":"SR Kim","year":"2020","unstructured":"Kim, S. R. et al. SGLT2 inhibition modulates NLRP3 inflammasome activity via ketones and insulin in diabetes with cardiovascular disease. Nat. Commun. 11, 2127 (2020).","journal-title":"Nat. Commun."},{"key":"1163_CR199","doi-asserted-by":"publisher","first-page":"773","DOI":"10.1016\/S0140-6736(24)01498-3","volume":"404","author":"J Deanfield","year":"2024","unstructured":"Deanfield, J. et al. Semaglutide and cardiovascular outcomes in patients with obesity and prevalent heart failure: a prespecified analysis of the SELECT trial. Lancet 404, 773\u2013786 (2024).","journal-title":"Lancet"},{"key":"1163_CR200","doi-asserted-by":"publisher","first-page":"463","DOI":"10.1038\/s41569-023-00849-3","volume":"20","author":"JR Ussher","year":"2023","unstructured":"Ussher, J. R. & Drucker, D. J. Glucagon-like peptide 1 receptor agonists: cardiovascular benefits and mechanisms of action. Nat. Rev. Cardiol. 20, 463\u2013474 (2023).","journal-title":"Nat. Rev. Cardiol."},{"key":"1163_CR201","doi-asserted-by":"publisher","first-page":"951","DOI":"10.1161\/CIRCRESAHA.121.318093","volume":"128","author":"M Koenen","year":"2021","unstructured":"Koenen, M., Hill, M. A., Cohen, P. & Sowers, J. R. Obesity, adipose tissue and vascular dysfunction. Circ. Res. 128, 951\u2013968 (2021).","journal-title":"Circ. Res."},{"key":"1163_CR202","doi-asserted-by":"publisher","first-page":"145","DOI":"10.1161\/atv.0000615456.97862.30","volume":"40","author":"J Helmstadter","year":"2020","unstructured":"Helmstadter, J. et al. Endothelial GLP-1 (glucagon-like peptide-1) receptor mediates cardiovascular protection by liraglutide in mice with experimental arterial hypertension. Arterioscler. Thromb. Vasc. Biol. 40, 145\u2013158 (2020).","journal-title":"Arterioscler. Thromb. Vasc. Biol."},{"key":"1163_CR203","doi-asserted-by":"publisher","first-page":"E947","DOI":"10.1152\/ajpendo.00400.2015","volume":"310","author":"R Wei","year":"2016","unstructured":"Wei, R. et al. Exenatide exerts direct protective effects on endothelial cells through the AMPK\/Akt\/eNOS pathway in a GLP-1 receptor-dependent manner. Am. J. Physiol. Endocrinol. Metab. 310, E947\u2013E957 (2016).","journal-title":"Am. J. Physiol. Endocrinol. Metab."},{"key":"1163_CR204","doi-asserted-by":"publisher","first-page":"44","DOI":"10.1016\/j.atherosclerosis.2017.04.001","volume":"261","author":"T Jojima","year":"2017","unstructured":"Jojima, T. et al. Liraglutide, a GLP-1 receptor agonist, inhibits vascular smooth muscle cell proliferation by enhancing AMP-activated protein kinase and cell cycle regulation, and delays atherosclerosis in ApoE deficient mice. Atherosclerosis 261, 44\u201351 (2017).","journal-title":"Atherosclerosis"},{"key":"1163_CR205","doi-asserted-by":"publisher","first-page":"375","DOI":"10.1016\/j.atherosclerosis.2011.12.039","volume":"221","author":"A Shiraki","year":"2012","unstructured":"Shiraki, A. et al. The glucagon-like peptide 1 analog liraglutide reduces TNF-\u03b1-induced oxidative stress and inflammation in endothelial cells. Atherosclerosis 221, 375\u2013382 (2012).","journal-title":"Atherosclerosis"},{"key":"1163_CR206","doi-asserted-by":"publisher","first-page":"1801","DOI":"10.1007\/s00125-017-4330-3","volume":"60","author":"A Vinue","year":"2017","unstructured":"Vinue, A. et al. The GLP-1 analogue lixisenatide decreases atherosclerosis in insulin-resistant mice by modulating macrophage phenotype. Diabetologia 60, 1801\u20131812 (2017).","journal-title":"Diabetologia"},{"key":"1163_CR207","doi-asserted-by":"publisher","first-page":"1030","DOI":"10.2337\/db09-1694","volume":"59","author":"M Arakawa","year":"2010","unstructured":"Arakawa, M. et al. Inhibition of monocyte adhesion to endothelial cells and attenuation of atherosclerotic lesion by a glucagon-like peptide-1 receptor agonist, exendin-4. Diabetes 59, 1030\u20131037 (2010).","journal-title":"Diabetes"},{"key":"1163_CR208","doi-asserted-by":"publisher","first-page":"198","DOI":"10.1210\/jc.2011-1508","volume":"97","author":"A Chaudhuri","year":"2012","unstructured":"Chaudhuri, A. et al. Exenatide exerts a potent antiinflammatory effect. J. Clin. Endocrinol. Metab. 97, 198\u2013207 (2012).","journal-title":"J. Clin. Endocrinol. Metab."},{"key":"1163_CR209","doi-asserted-by":"publisher","first-page":"2263","DOI":"10.1161\/CIRCULATIONAHA.110.981738","volume":"123","author":"JP Stasch","year":"2011","unstructured":"Stasch, J. P., Pacher, P. & Evgenov, O. V. Soluble guanylate cyclase as an emerging therapeutic target in cardiopulmonary disease. Circulation 123, 2263\u20132273 (2011).","journal-title":"Circulation"},{"key":"1163_CR210","doi-asserted-by":"publisher","DOI":"10.1038\/ncomms9482","volume":"6","author":"R Thoonen","year":"2015","unstructured":"Thoonen, R. et al. Cardiovascular and pharmacological implications of haem-deficient NO-unresponsive soluble guanylate cyclase knock-in mice. Nat. Commun. 6, 8482 (2015).","journal-title":"Nat. Commun."},{"key":"1163_CR211","doi-asserted-by":"publisher","first-page":"1883","DOI":"10.1056\/NEJMoa1915928","volume":"382","author":"PW Armstrong","year":"2020","unstructured":"Armstrong, P. W. et al. Vericiguat in patients with heart failure and reduced ejection fraction. N. Engl. J. Med. 382, 1883\u20131893 (2020).","journal-title":"N. Engl. J. Med."},{"key":"1163_CR212","doi-asserted-by":"publisher","DOI":"10.1161\/CIRCULATIONAHA.123.066523","author":"B Zhang","year":"2025","unstructured":"Zhang, B. et al. Reactivation of oxidized soluble guanylate cyclase as a novel treatment strategy to slow progression of calcific aortic valve stenosis: preclinical and randomized clinical trials to assess safety and efficacy. Circulation https:\/\/doi.org\/10.1161\/CIRCULATIONAHA.123.066523 (2025).","journal-title":"Circulation"},{"key":"1163_CR213","doi-asserted-by":"publisher","first-page":"683","DOI":"10.1093\/eurheartj\/ehab757","volume":"43","author":"S Kraler","year":"2022","unstructured":"Kraler, S., Blaser, M. C., Aikawa, E., Camici, G. G. & Luscher, T. F. Calcific aortic valve disease: from molecular and cellular mechanisms to medical therapy. Eur. Heart J. 43, 683\u2013697 (2022).","journal-title":"Eur. Heart J."},{"key":"1163_CR214","doi-asserted-by":"publisher","first-page":"432","DOI":"10.1016\/j.phrs.2010.06.008","volume":"62","author":"A Schafer","year":"2010","unstructured":"Schafer, A., Fraccarollo, D., Werner, L. & Bauersachs, J. Guanylyl cyclase activator ataciguat improves vascular function and reduces platelet activation in heart failure. Pharmacol. Res. 62, 432\u2013438 (2010).","journal-title":"Pharmacol. Res."},{"key":"1163_CR215","doi-asserted-by":"publisher","first-page":"1386","DOI":"10.1073\/pnas.0304264101","volume":"101","author":"A Ahluwalia","year":"2004","unstructured":"Ahluwalia, A. et al. Antiinflammatory activity of soluble guanylate cyclase: cGMP-dependent down-regulation of P-selectin expression and leukocyte recruitment. Proc. Natl Acad. Sci. USA 101, 1386\u20131391 (2004).","journal-title":"Proc. Natl Acad. Sci. USA"},{"key":"1163_CR216","doi-asserted-by":"publisher","first-page":"28263","DOI":"10.1073\/pnas.2000466117","volume":"117","author":"R Flores-Costa","year":"2020","unstructured":"Flores-Costa, R. et al. Stimulation of soluble guanylate cyclase exerts antiinflammatory actions in the liver through a VASP\/NF-\u03baB\/NLRP3 inflammasome circuit. Proc. Natl Acad. Sci. USA 117, 28263\u201328274 (2020).","journal-title":"Proc. Natl Acad. Sci. USA"},{"key":"1163_CR217","doi-asserted-by":"publisher","first-page":"1675","DOI":"10.1002\/ejhf.1787","volume":"22","author":"F Kramer","year":"2020","unstructured":"Kramer, F. et al. Evaluation of high-sensitivity C-reactive protein and uric acid in vericiguat-treated patients with heart failure with reduced ejection fraction. Eur. J. Heart Fail. 22, 1675\u20131683 (2020).","journal-title":"Eur. J. Heart Fail."},{"key":"1163_CR218","doi-asserted-by":"publisher","first-page":"1512","DOI":"10.1001\/jama.2020.15922","volume":"324","author":"PW Armstrong","year":"2020","unstructured":"Armstrong, P. W. et al. Effect of vericiguat vs placebo on quality of life in patients with heart failure and preserved ejection fraction: the vitality-HFpEF randomized clinical trial. JAMA 324, 1512\u20131521 (2020).","journal-title":"JAMA"},{"key":"1163_CR219","doi-asserted-by":"publisher","first-page":"1119","DOI":"10.1093\/eurheartj\/ehw593","volume":"38","author":"B Pieske","year":"2017","unstructured":"Pieske, B. et al. Vericiguat in patients with worsening chronic heart failure and preserved ejection fraction: results of the soluble guanylate cyclase stimulator in heart failure patients with PRESERVED EF (SOCRATES-PRESERVED) study. Eur. Heart J. 38, 1119\u20131127 (2017).","journal-title":"Eur. Heart J."},{"key":"1163_CR220","doi-asserted-by":"publisher","first-page":"1420","DOI":"10.1002\/ejhf.678","volume":"18","author":"WA Heggermont","year":"2016","unstructured":"Heggermont, W. A., Papageorgiou, A. P., Heymans, S. & van Bilsen, M. Metabolic support for the heart: complementary therapy for heart failure? Eur. J. Heart Fail. 18, 1420\u20131429 (2016).","journal-title":"Eur. J. Heart Fail."},{"key":"1163_CR221","doi-asserted-by":"publisher","first-page":"311","DOI":"10.1016\/j.atherosclerosis.2011.10.027","volume":"221","author":"L Gao","year":"2012","unstructured":"Gao, L. et al. Effects of coenzyme Q10 on vascular endothelial function in humans: a meta-analysis of randomized controlled trials. Atherosclerosis 221, 311\u2013316 (2012).","journal-title":"Atherosclerosis"},{"key":"1163_CR222","doi-asserted-by":"publisher","first-page":"37","DOI":"10.1007\/s00395-023-01008-y","volume":"118","author":"C Homilius","year":"2023","unstructured":"Homilius, C. et al. Ketone body 3-hydroxybutyrate elevates cardiac output through peripheral vasorelaxation and enhanced cardiac contractility. Basic Res. Cardiol. 118, 37 (2023).","journal-title":"Basic Res. Cardiol."},{"key":"1163_CR223","doi-asserted-by":"publisher","DOI":"10.1161\/JAHA.123.033744","volume":"13","author":"JM Seefeldt","year":"2024","unstructured":"Seefeldt, J. M. et al. Short-chain fatty acid butyrate is an inotropic agent with vasorelaxant and cardioprotective properties. J. Am. Heart Assoc. 13, e033744 (2024).","journal-title":"J. Am. Heart Assoc."},{"key":"1163_CR224","doi-asserted-by":"publisher","first-page":"850","DOI":"10.3390\/biom13050850","volume":"13","author":"ZY Xu","year":"2023","unstructured":"Xu, Z. Y., Jing, X. & Xiong, X. D. Emerging role and mechanism of the FTO gene in cardiovascular diseases. Biomolecules 13, 850 (2023).","journal-title":"Biomolecules"},{"key":"1163_CR225","doi-asserted-by":"publisher","first-page":"1511","DOI":"10.1056\/NEJMoa1602001","volume":"374","author":"EJ Velazquez","year":"2016","unstructured":"Velazquez, E. J. et al. Coronary-artery bypass surgery in patients with ischemic cardiomyopathy. N. Engl. J. Med. 374, 1511\u20131520 (2016).","journal-title":"N. Engl. J. Med."},{"key":"1163_CR226","doi-asserted-by":"publisher","first-page":"1351","DOI":"10.1056\/NEJMoa2206606","volume":"387","author":"D Perera","year":"2022","unstructured":"Perera, D. et al. Percutaneous revascularization for ischemic left ventricular dysfunction. N. Engl. J. Med. 387, 1351\u20131360 (2022).","journal-title":"N. Engl. J. Med."},{"key":"1163_CR227","doi-asserted-by":"publisher","first-page":"72","DOI":"10.1093\/eurheartj\/ehae672","volume":"46","author":"JE Bloom","year":"2025","unstructured":"Bloom, J. E. et al. Coronary artery bypass grafting vs. percutaneous coronary intervention in severe ischaemic cardiomyopathy: long-term survival. Eur. Heart J. 46, 72\u201380 (2025).","journal-title":"Eur. Heart J."},{"key":"1163_CR228","doi-asserted-by":"publisher","first-page":"437","DOI":"10.1056\/NEJMoa1808783","volume":"380","author":"DP Taggart","year":"2019","unstructured":"Taggart, D. P. et al. Bilateral versus single internal-thoracic-artery grafts at 10 years. N. Engl. J. Med. 380, 437\u2013446 (2019).","journal-title":"N. Engl. J. Med."},{"key":"1163_CR229","doi-asserted-by":"publisher","first-page":"295","DOI":"10.1016\/j.jacc.2023.05.025","volume":"82","author":"K Mavromatis","year":"2023","unstructured":"Mavromatis, K. et al. Complete revascularization and angina-related health status in the ISCHEMIA trial. J. Am. Coll. Cardiol. 82, 295\u2013313 (2023).","journal-title":"J. Am. Coll. Cardiol."},{"key":"1163_CR230","doi-asserted-by":"publisher","first-page":"1503","DOI":"10.1056\/NEJMoa070829","volume":"356","author":"WE Boden","year":"2007","unstructured":"Boden, W. E. et al. Optimal medical therapy with or without PCI for stable coronary disease. N. Engl. J. Med. 356, 1503\u20131516 (2007).","journal-title":"N. Engl. J. Med."},{"key":"1163_CR231","doi-asserted-by":"publisher","first-page":"31","DOI":"10.1016\/S0140-6736(17)32714-9","volume":"391","author":"R Al-Lamee","year":"2018","unstructured":"Al-Lamee, R. et al. Percutaneous coronary intervention in stable angina (ORBITA): a double-blind, randomised controlled trial. Lancet 391, 31\u201340 (2018).","journal-title":"Lancet"},{"key":"1163_CR232","doi-asserted-by":"publisher","first-page":"181","DOI":"10.1093\/eurheartj\/ehad579","volume":"45","author":"KL Gould","year":"2024","unstructured":"Gould, K. L. et al. Coronary flow capacity and survival prediction after revascularization: physiological basis and clinical implications. Eur. Heart J. 45, 181\u2013194 (2024).","journal-title":"Eur. Heart J."},{"key":"1163_CR233","doi-asserted-by":"publisher","DOI":"10.1161\/CIRCINTERVENTIONS.122.012527","volume":"16","author":"SE Fremes","year":"2023","unstructured":"Fremes, S. E. et al. STICH3C: rationale and study protocol. Circ. Cardiovasc. Interv. 16, e012527 (2023).","journal-title":"Circ. Cardiovasc. Interv."},{"key":"1163_CR234","doi-asserted-by":"publisher","unstructured":"ISRCTN Registry. https:\/\/doi.org\/10.1186\/ISRCTN29654606 (2025).","DOI":"10.1186\/ISRCTN29654606"},{"key":"1163_CR235","doi-asserted-by":"publisher","first-page":"532","DOI":"10.1093\/eurheartj\/ehae853","volume":"46","author":"PC Revaiah","year":"2025","unstructured":"Revaiah, P. C., Onuma, Y. & Serruys, P. W. Non-ST elevation acute coronary syndrome with multivessel disease: need for randomized trials. Eur. Heart J. 46, 532\u2013534 (2025).","journal-title":"Eur. Heart J."},{"key":"1163_CR236","doi-asserted-by":"publisher","first-page":"518","DOI":"10.1093\/eurheartj\/ehae700","volume":"46","author":"E Omerovic","year":"2025","unstructured":"Omerovic, E. et al. Percutaneous vs. surgical revascularization of non-ST-segment elevation myocardial infarction with multivessel disease: the SWEDEHEART registry. Eur. Heart J. 46, 518\u2013531 (2025).","journal-title":"Eur. Heart J."},{"key":"1163_CR237","doi-asserted-by":"publisher","first-page":"56","DOI":"10.1172\/JCI108079","volume":"56","author":"W Grossman","year":"1975","unstructured":"Grossman, W., Jones, D. & McLaurin, L. P. Wall stress and patterns of hypertrophy in the human left ventricle. J. Clin. Invest. 56, 56\u201364 (1975).","journal-title":"J. Clin. Invest."},{"key":"1163_CR238","doi-asserted-by":"publisher","first-page":"2023","DOI":"10.3390\/ijms22042023","volume":"22","author":"M Perera-Gonzalez","year":"2021","unstructured":"Perera-Gonzalez, M. et al. The role of tenascin c in cardiac reverse remodeling following banding-debanding of the ascending aorta. Int. J. Mol. Sci. 22, 2023 (2021).","journal-title":"Int. J. Mol. Sci."},{"key":"1163_CR239","doi-asserted-by":"publisher","first-page":"240","DOI":"10.1016\/0002-9149(89)90469-4","volume":"64","author":"JC Mohan","year":"1989","unstructured":"Mohan, J. C., Khalilullah, M. & Arora, R. Left ventricular intrinsic contractility in pure rheumatic mitral stenosis. Am. J. Cardiol. 64, 240\u2013242 (1989).","journal-title":"Am. J. Cardiol."},{"key":"1163_CR240","doi-asserted-by":"publisher","first-page":"1022","DOI":"10.1161\/01.CIR.91.4.1022","volume":"91","author":"M Enriquez-Sarano","year":"1995","unstructured":"Enriquez-Sarano, M. et al. Valve repair improves the outcome of surgery for mitral regurgitation. a multivariate analysis. Circulation 91, 1022\u20131028 (1995).","journal-title":"Circulation"},{"key":"1163_CR241","first-page":"802","volume":"13","author":"M Schemmelmann","year":"2024","unstructured":"Schemmelmann, M., Kelm, M. & Jung, C. The microcirculation in cardiogenic shock. Eur. Heart J. Acute Cardiovasc. Care 13, 802\u2013809 (2024).","journal-title":"Eur. Heart J. Acute Cardiovasc. Care"},{"key":"1163_CR242","doi-asserted-by":"publisher","first-page":"9","DOI":"10.1001\/jamacardio.2024.4197","volume":"10","author":"NLJ Udesen","year":"2025","unstructured":"Udesen, N. L. J. et al. Microaxial flow pump hemodynamic and metabolic effects in infarct-related cardiogenic shock: a substudy of the danger shock randomized clinical trial. JAMA Cardiol. 10, 9\u201316 (2025).","journal-title":"JAMA Cardiol."},{"key":"1163_CR243","doi-asserted-by":"publisher","first-page":"1049","DOI":"10.1053\/j.jvca.2024.12.007","volume":"39","author":"JS Saggu","year":"2025","unstructured":"Saggu, J. S. et al. Mechanical circulatory support for acute myocardial infarction cardiogenic shock: review and recent updates. J. Cardiothorac. Vasc. Anesth. 39, 1049\u20131066 (2025).","journal-title":"J. Cardiothorac. Vasc. Anesth."},{"key":"1163_CR244","doi-asserted-by":"publisher","first-page":"94","DOI":"10.1016\/j.amjcard.2022.06.059","volume":"181","author":"K Bhatia","year":"2022","unstructured":"Bhatia, K. et al. Meta-analysis comparing venoarterial extracorporeal membrane oxygenation with or without impella in patients with cardiogenic shock. Am. J. Cardiol. 181, 94\u2013101 (2022).","journal-title":"Am. J. Cardiol."},{"key":"1163_CR245","doi-asserted-by":"publisher","first-page":"2328","DOI":"10.1056\/NEJMoa2312572","volume":"390","author":"JE Moller","year":"2024","unstructured":"Moller, J. E., Hassager, C. & DanGer Shock, I. Microaxial flow pump in infarct-related cardiogenic shock. Reply. N. Engl. J. Med. 390, 2328\u20132330 (2024).","journal-title":"N. Engl. J. Med."},{"key":"1163_CR246","doi-asserted-by":"publisher","first-page":"1478","DOI":"10.1016\/j.healun.2024.05.015","volume":"43","author":"J Fried","year":"2024","unstructured":"Fried, J. et al. Clinical outcomes among cardiogenic shock patients supported with high-capacity Impella axial flow pumps: a report from the cardiogenic shock working group. J. Heart Lung Transpl. 43, 1478\u20131488 (2024).","journal-title":"J. Heart Lung Transpl."},{"key":"1163_CR247","doi-asserted-by":"publisher","DOI":"10.1007\/s00380-025-02516-8","author":"K Yahagi","year":"2025","unstructured":"Yahagi, K. et al. Impact of lactate levels on admission in STEMI patients with cardiogenic shock treated with IMPELLA. Heart Vessels https:\/\/doi.org\/10.1007\/s00380-025-02516-8 (2025).","journal-title":"Heart Vessels"},{"key":"1163_CR248","doi-asserted-by":"publisher","first-page":"9","DOI":"10.1016\/S0140-6736(98)11181-9","volume":"353","author":"CIBIS-II Investigators and Committees.","year":"1999","unstructured":"CIBIS-II Investigators and Committees. The cardiac insufficiency bisoprolol study II (CIBIS-II): a randomised trial. Lancet 353, 9\u201313 (1999).","journal-title":"Lancet"},{"key":"1163_CR249","doi-asserted-by":"publisher","first-page":"1295","DOI":"10.1001\/jama.283.10.1295","volume":"283","author":"A Hjalmarson","year":"2000","unstructured":"Hjalmarson, A. et al. Effects of controlled-release metoprolol on total mortality, hospitalizations, and well-being in patients with heart failure: the Metoprolol CR\/XL randomized intervention trial in congestive heart failure (MERIT-HF). merit-hf study group. JAMA 283, 1295\u20131302 (2000).","journal-title":"JAMA"},{"key":"1163_CR250","doi-asserted-by":"publisher","first-page":"1349","DOI":"10.1056\/NEJM199605233342101","volume":"334","author":"M Packer","year":"1996","unstructured":"Packer, M. et al. The effect of carvedilol on morbidity and mortality in patients with chronic heart failure. U.S. carvedilol heart failure study group. N. Engl. J. Med. 334, 1349\u20131355 (1996).","journal-title":"N. Engl. J. Med."},{"key":"1163_CR251","doi-asserted-by":"publisher","first-page":"215","DOI":"10.1093\/eurheartj\/ehi115","volume":"26","author":"MD Flather","year":"2005","unstructured":"Flather, M. D. et al. Randomized trial to determine the effect of nebivolol on mortality and cardiovascular hospital admission in elderly patients with heart failure (SENIORS). Eur. Heart J. 26, 215\u2013225 (2005).","journal-title":"Eur. Heart J."},{"key":"1163_CR252","doi-asserted-by":"publisher","first-page":"993","DOI":"10.1056\/NEJMoa1409077","volume":"371","author":"JJ McMurray","year":"2014","unstructured":"McMurray, J. J. et al. Angiotensin-neprilysin inhibition versus enalapril in heart failure. N. Engl. J. Med. 371, 993\u20131004 (2014).","journal-title":"N. Engl. J. Med."},{"key":"1163_CR253","doi-asserted-by":"publisher","first-page":"293","DOI":"10.1056\/NEJM199108013250501","volume":"325","author":"SOLVD Investigators","year":"1991","unstructured":"SOLVD Investigators et al. Effect of enalapril on survival in patients with reduced left ventricular ejection fractions and congestive heart failure. N. Engl. J. Med. 325, 293\u2013302 (1991).","journal-title":"N. Engl. J. Med."},{"key":"1163_CR254","doi-asserted-by":"publisher","first-page":"1667","DOI":"10.1056\/NEJMoa010713","volume":"345","author":"JN Cohn","year":"2001","unstructured":"Cohn, J. N., Tognoni, G. & Valsartan Heart Failure Trial Investigators. A randomized trial of the angiotensin-receptor blocker valsartan in chronic heart failure. N. Engl. J. Med. 345, 1667\u20131675 (2001).","journal-title":"N. Engl. J. Med."},{"key":"1163_CR255","doi-asserted-by":"publisher","first-page":"709","DOI":"10.1056\/NEJM199909023411001","volume":"341","author":"B Pitt","year":"1999","unstructured":"Pitt, B. et al. The effect of spironolactone on morbidity and mortality in patients with severe heart failure. randomized aldactone evaluation study investigators. N. Engl. J. Med. 341, 709\u2013717 (1999).","journal-title":"N. Engl. J. Med."},{"key":"1163_CR256","doi-asserted-by":"publisher","first-page":"1475","DOI":"10.1056\/NEJMoa2407107","volume":"391","author":"SD Solomon","year":"2024","unstructured":"Solomon, S. D. et al. Finerenone in heart failure with mildly reduced or preserved ejection fraction. N. Engl. J. Med. 391, 1475\u20131485 (2024).","journal-title":"N. Engl. J. Med."},{"key":"1163_CR257","doi-asserted-by":"publisher","first-page":"1451","DOI":"10.1056\/NEJMoa2107038","volume":"385","author":"SD Anker","year":"2021","unstructured":"Anker, S. D. et al. Empagliflozin in heart failure with a preserved ejection fraction. N. Engl. J. Med. 385, 1451\u20131461 (2021).","journal-title":"N. Engl. J. Med."},{"key":"1163_CR258","doi-asserted-by":"publisher","first-page":"1413","DOI":"10.1056\/NEJMoa2022190","volume":"383","author":"M Packer","year":"2020","unstructured":"Packer, M. et al. Cardiovascular and renal outcomes with empagliflozin in heart failure. N. Engl. J. Med. 383, 1413\u20131424 (2020).","journal-title":"N. Engl. J. Med."},{"key":"1163_CR259","doi-asserted-by":"publisher","first-page":"1089","DOI":"10.1056\/NEJMoa2206286","volume":"387","author":"SD Solomon","year":"2022","unstructured":"Solomon, S. D. et al. Dapagliflozin in heart failure with mildly reduced or preserved ejection fraction. N. Engl. J. Med. 387, 1089\u20131098 (2022).","journal-title":"N. Engl. J. Med."},{"key":"1163_CR260","doi-asserted-by":"publisher","first-page":"1995","DOI":"10.1056\/NEJMoa1911303","volume":"381","author":"JJV McMurray","year":"2019","unstructured":"McMurray, J. J. V. et al. Dapagliflozin in patients with heart failure and reduced ejection fraction. N. Engl. J. Med. 381, 1995\u20132008 (2019).","journal-title":"N. Engl. J. Med."},{"key":"1163_CR261","doi-asserted-by":"publisher","first-page":"949","DOI":"10.1016\/S0140-6736(24)01643-X","volume":"404","author":"MN Kosiborod","year":"2024","unstructured":"Kosiborod, M. N. et al. Semaglutide versus placebo in patients with heart failure and mildly reduced or preserved ejection fraction: a pooled analysis of the SELECT, FLOW, STEP-HFpEF, and STEP-HFpEF DM randomised trials. Lancet 404, 949\u2013961 (2024).","journal-title":"Lancet"},{"key":"1163_CR262","doi-asserted-by":"publisher","first-page":"545","DOI":"10.1038\/s41569-024-00997-0","volume":"21","author":"B Bozkurt","year":"2024","unstructured":"Bozkurt, B. Contemporary pharmacological treatment and management of heart failure. Nat. Rev. Cardiol. 21, 545\u2013555 (2024).","journal-title":"Nat. Rev. Cardiol."}],"container-title":["Nature Reviews Cardiology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41569-025-01163-w.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41569-025-01163-w","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41569-025-01163-w.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,9,15]],"date-time":"2025-09-15T12:02:18Z","timestamp":1757937738000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41569-025-01163-w"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,6,22]]},"references-count":262,"journal-issue":{"issue":"10","published-print":{"date-parts":[[2025,10]]}},"alternative-id":["1163"],"URL":"https:\/\/doi.org\/10.1038\/s41569-025-01163-w","relation":{},"ISSN":["1759-5002","1759-5010"],"issn-type":[{"value":"1759-5002","type":"print"},{"value":"1759-5010","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,6,22]]},"assertion":[{"value":"30 April 2025","order":1,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"22 June 2025","order":2,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"L.L. is a co-inventor on the international patent WO\/2020\/226993 filed in April 2020. The patent relates to the use of antibodies that specifically bind to IL-1\u03b1 to reduce various sequelae of ischaemia\u2013reperfusion injury to the central nervous system. L.L. has received speaker fees from Daiichi-Sankyo, he is a counsellor of the European Society for Clinical Investigation and has received funding from the Italian Ministry of Health, the Novartis Foundation for Medical-biological Research and the Swiss Heart Foundation. D.J.H. has received consultant fees from Boehringer Ingelheim International and Faraday Pharmaceuticals, has received honoraria from Servier, and has received research funding from AstraZeneca, Merck Sharp & Dohme Corp and Novo Nordisk. S.K. has received speaker fees from Roche Diagnostics and the Foundation for Cardiovascular Research \u2013 Zurich Heart House and has received travel support from 4TEEN4 Pharmaceuticals, European Atherosclerosis Society, European Society of Cardiology, European Society of Clinical Investigation, Foundation for Cardiovascular Research \u2013 Zurich Heart House, PAM Theragnostics and Sphingotec. The other authors declare no competing interests.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}]}}